Filed pursuant to Rule
424(b)(5)
Registration No. 333-252358
PROSPECTUS SUPPLEMENT
(To Prospectus dated February 16,
2021)

Up to $10,000,000 of Shares of Common Stock
AiAdvertising , Inc. is offering up to $10,000,000 in shares of our
common stock to GHS Investments, LLC (“GHS”) under a purchase
agreement entered into on March 28, 2022 (the “Purchase
Agreement”). GHS may be deemed to be an “underwriter” within the
meaning of Section 2(a)(11) of the Securities Act. At any time
until March 28, 2023, subject to the terms of the Purchase
Agreement, the Company shall have the right, but not the
obligation, to direct the Investor by its delivery to the Investor
of a Purchase Notice from time to time, to purchase a minimum of
ten thousand dollars ($10,000) worth of shares and up to a maximum
of the lower of: (1) one hundred percent (100%) of the average
daily trading dollar volume for the Company’s common stock during
the ten Trading Days preceding the Purchase Date; or (2) one
million dollars ($1,000,000). See “Purchase Agreement with GHS
Investments, LLC on page S-4 of this prospectus supplement for a
description of the Purchase Agreement.
Our common stock is quoted on the OTC Pink under the symbol “AIAD.”
On March 28, 2022, the last reported sales price of our common
stock on the OTC Pink was $0.0290 per share.
Investing in our securities involves significant risks. See
“Risk Factors” beginning on page S-5 of this prospectus supplement
and in the documents incorporated by reference into this prospectus
supplement.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this
prospectus supplement. Any representation to the contrary is a
criminal offense.
The date of this prospectus supplement is March 28, 2022.
TABLE OF CONTENTS
PROSPECTUS
You should rely only on the information incorporated by reference
or provided in this prospectus supplement and the accompanying
prospectus. We have not have authorized anyone to provide you with
different information. If anyone provides you with different or
inconsistent information, you should not rely on it. This
prospectus supplement and the accompanying prospectus do not
constitute an offer to sell, or a solicitation of an offer to
purchase, the securities offered by this prospectus supplement and
the accompanying prospectus in any jurisdiction where it is
unlawful to make such offer or solicitation. You should assume that
the information contained in this prospectus supplement or the
accompanying prospectus, or any document incorporated by reference
in this prospectus supplement or the accompanying prospectus, is
accurate only as of the date of those respective
documents. Neither the delivery of this prospectus supplement
nor any distribution of securities pursuant to this prospectus
supplement shall, under any circumstances, create any implication
that there has been no change in the information set forth or
incorporated by reference into this prospectus supplement or in our
affairs since the date of this prospectus supplement. Our business,
financial condition, results of operations and prospects may have
changed since that date.
ABOUT THIS
PROSPECTUS SUPPLEMENT
This document is in two parts. The first part is this prospectus
supplement, which describes the specific terms of this offering of
securities. The second part is the accompanying prospectus, which
provides more general information, some of which may not apply to
this offering. The information included or incorporated by
reference in this prospectus supplement also adds to, updates and
changes information contained or incorporated by reference in the
accompanying prospectus. If information included or incorporated by
reference in this prospectus supplement is inconsistent with the
accompanying prospectus or the information incorporated by
reference therein, then this prospectus supplement or the
information incorporated by reference in this prospectus supplement
will apply and will supersede the information in the accompanying
prospectus and the documents incorporated by reference therein.
This prospectus supplement is part of a registration statement that
we filed with the Securities and Exchange Commission, or the SEC,
using a “shelf” registration process, under the Securities Act of
1933, as amended (the “Securities Act”).
Under the shelf registration process, we may from time to time
offer and sell any combination of the securities described in the
accompanying prospectus up to a total dollar amount of
$100,000,000, of which this offering is a part.
In this prospectus supplement and the accompanying prospectus,
unless the context otherwise requires, references to AiAdvertising”
the “Company,” “we,” “us,” “our” refer to AiAdvertising, Inc.
together with its subsidiaries.
PROSPECTUS
SUPPLEMENT SUMMARY
This summary highlights selected information about our company,
this offering and information appearing elsewhere in this
prospectus supplement, in the accompanying prospectus, and in the
documents we incorporate by reference. This summary is not complete
and does not contain all the information that you should consider
before investing in our securities. You should read this entire
prospectus supplement and the accompanying prospectus carefully,
including the “Risk Factors” contained in this prospectus
supplement beginning on page S-5, and the risk factors, financial
statements and notes incorporated by reference herein, before
making an investment decision. This prospectus supplement may add
to, update or change information in the accompanying
prospectus.
Company Overview
AiAdvertising’s primary focus is to disrupt the digital advertising
world by offering a solution that harnesses the power of artificial
intelligence (AI) to enable marketers to increase productivity,
efficiency and performance.
Our proprietary software empowers marketers by intelligently
automating data- driven, repetitive tasks, and improving their
ability to make predictions at scale.
In the past we have contracted with clients to deliver technology
enabled services. These services were project-based and delivered
against a contracted SOW (Statement of Work). Beginning in the
fourth quarter of 2022, we pivoted to a software licensing and
delivery model, whereby our software is centrally hosted and
licensed on a monthly subscription basis. We believe this shift
towards SaaS recurring revenue can potentially be highly valuable
to the Company and its shareholders.
Our Software Platform
Our software platform harnesses the power of machine learning and
artificial intelligence to eliminate guesswork, predict what works,
and prove advertising's impact on financial results. Key features
of our platform include:
Alignment - We start with the end in mind and use a
comprehensive discovery process to outline goals and key
performance indicators (KPIs) to connect them to revenue targets.
By aligning on the desired outcomes, our platform renders marketing
and content calendars built upon the defined goals and
objectives.
Insights - AI Data Services inventories and aggregates data
from all of a client’s tools, such as customer relationship
management (CRM), sales, marketing, accounting, and customer
service tools into a unified data warehouse where it is cleaned,
organized, and tagged. This allows the artificial intelligence in
our platform to segment customers and prospective customers by
revealing patterns, signals, and insights to draw commonalities
between points and grouping them into personas (fictional
characters used to represent larger groups that share
similarities). Once these audiences are segmented, we use unique
engagement predictors leveraging psychographic models to identify
motivations, behaviors, influences, and interests. These insights
inform the type of creative assets these audience segments will
most likely respond to. The models are leveraged to find new
incremental audiences.
Activate – Our AI platform scores our clients’ existing
creative assets and intelligently recommends enhancements to
optimize performance. Our AI leverages the audience personas of who
will see the ads to accurately personalize and predict more
successful creative assets. This predictive engine allows clients
to know the likelihood that their ad will resonate with their
audiences before placing the ad. Our AI can then dynamically create
hundreds or thousands of variations of highly targeted ads based on
what our AI knows about the specific audience personas. Combined
with our software, our teams then help our clients place these ads
through the channels that will produce the highest results.
Decisions – The AiAd dashboard aggregates data from all
marketing channels to connect marketing strategies to financial
results. Our platform continuously monitors and validates each
campaign's impact and provides recommendations to maximize their
effectiveness. Leveraging machine learning, it provides ongoing
analysis and optimization of behavioral profiles, creative,
audience segments, and media activation. Our platform empowers
marketers to know what works, what doesn't, what's next, and why so
they can make the most informed decisions.
Corporate Information
We were incorporated in Nevada on January 22, 2022. Our principal
executive offices are located at 321 Sixth Street, San Antonio, TX
78215, and our telephone number is 805-964-3313. Our website
address is www.aiadvertising.com. The information
contained therein or connected thereto shall not be deemed to be
incorporated into this prospectus or the registration statement of
which it forms a part. The information on our website is not part
of this prospectus. Effective August 5, 2021, the Company changed
its name from CloudCommerce, Inc. to AiAdvertising, Inc.
THE
OFFERING
Securities we are offering |
|
Up to $10,000,000 of shares of our common stock
we may sell from time to time, at our sole discretion, subject to
the terms of the Purchase Agreement to GHS over the next year in
accordance with the Purchase Agreement. |
|
|
|
Common stock to be outstanding after the
offering |
|
1,400,384,104 shares |
|
|
|
Use of proceeds |
|
We estimate the net proceeds to
us from this offering will be approximately $9,765,000 million
after deducting estimated offering expenses payable by us. We
intend to use the net proceeds from the sale of the securities
offered by this prospectus for working capital and general
corporate purposes. |
|
|
|
OTC Pink symbol for common
stock |
|
Our common stock is quoted on the
OTC Pink under the symbol “AIAD.” |
|
|
|
Risk factors |
|
Investing in our securities
involves significant risks. See “Risk Factors” beginning on page
S-5 of this prospectus supplement. |
The number of shares of common stock shown above to be outstanding
after this offering is based on 1,055,556,518 shares outstanding as
of March 23, 2022, and excludes:
|
● |
450,625,000 shares of
common stock issuable upon conversion of 18,025 outstanding shares
of Series B Preferred Stock; |
|
|
|
|
● |
144,250,000 shares of
common stock issuable upon conversion of 14,425 outstanding shares
of Series C Preferred Stock; |
|
|
|
|
● |
215,052,500 shares of
common stock issuable upon conversion of 86,021 outstanding shares
of Series D Preferred Stock; |
|
|
|
|
● |
20,000,000 shares of
common stock issuable upon conversion of 10,000 outstanding shares
of Series E Preferred Stock; |
|
|
|
|
● |
136,684,211 shares of
common stock issuable upon conversion of 2,597 outstanding shares
of Series G Preferred Stock; |
|
|
|
|
● |
890,733,332 shares of
common stock issuable upon exercise of outstanding stock options,
with a weighted average exercise price of $.0093 per share;
and |
|
|
|
|
● |
162,709,169 shares of common stock issuable upon exercise of
warrants, with an exercise price of $0.0479.
|
Purchase Agreement with GHS Investments,
LLC
On March 28, 2022, we entered into the Purchase Agreement with GHS,
which provides that, upon the terms and subject to the conditions
and limitations set forth therein, we have the right to sell to GHS
up to $10,000,000 of shares (“Purchase Shares”) of our common stock
as described below.
The Company has the right, in its sole discretion, subject to the
conditions and limitations in the Purchase Agreement, to direct
GHS, by delivery of a purchase notice from time to time (a
“Purchase Notice”) to purchase (each, a “Purchase”) over the
one-year term of the Purchase Agreement, a minimum of $10,000 and
up to a maximum of the lower of: (1) one hundred percent (100%) of
the average daily trading dollar volume of the Company’s common
stock during the ten trading days preceding the Purchase Date; or
(2) one million dollars ($1,000,000), provided that the parties may
agree to waive such limitations. The aggregate value of Purchase
Shares sold to GHS may not exceed $10,000,000. Each Purchase Notice
will set forth the Purchase Price and number of Purchase Shares in
accordance with the terms of this Agreement.
The number of Purchase Shares we will issue under each Purchase
will be equal to 112.5% of the Purchase Amount sold under such
Purchase, divided by the Purchase Price per share (as defined under
the Purchase Agreement).
The Purchase Price is defined as the lower of (a) 90% of the lowest
volume weighted average price during the Valuation Period; or (b)
the Closing Price for our common stock on the trading day preceding
the date of the Purchase Notice. The Purchase Price will be subject
to a floor of $.01 per share, at or below which the Company will
not deliver a Purchase Notice. The Valuation Period is the ten
consecutive business days immediately preceding, but not including,
the date a Purchase Notice is delivered.
The Purchase Agreement prohibits us from directing GHS to purchase
any shares of common stock if those shares, when aggregated with
all other shares of our common stock then beneficially owned by GHS
and its affiliates, would result in GHS and its affiliates having
beneficial ownership, at any single point in time, of more than
4.99% of the then total outstanding shares of our common stock.
There are no trading volume requirements or restrictions under the
Purchase Agreement. We will control the timing and amount of any
sales of our common stock to GHS.
Events of default under the Purchase Agreement include the
following:
|
● |
the effectiveness of the registration statement for the Purchase
Shares lapses for any reason or is unavailable for the issuance to
or resale by GHS of the Purchase Shares;
|
|
● |
the
suspension of our common stock from trading for a period of two
business days; |
|
● |
the delisting of the Company’s common stock from the OTC Pink;
provided, however, that the common stock is not immediately
thereafter trading on the Nasdaq Capital Market, New York Stock
Exchange, the Nasdaq Global Market, the Nasdaq Global Select
Market, the NYSE American, or the OTCQB or OTCQX;
|
|
● |
the failure for any reason by the transfer agent to issue Purchase
Shares to GHS within three business days after the applicable date
on which GHS is entitled to receive such securities;
|
|
● |
any breach of the representations and warranties or covenants
contained in the Purchase Agreement if such breach would reasonably
be expected to have a material adverse effect and such breach is
not cured within five business days;
|
|
● |
insolvency or bankruptcy proceedings are commenced by or against
us, as more fully described in the Purchase Agreement; or
|
|
● |
if at
any time we are not eligible to transfer our common stock
electronically via DWAC. |
So long as an event of default (all of which are outside the
control of GHS) has occurred and is continuing, the Company may not
deliver a Purchase Notice to GHS.
This offering will terminate on the date that all shares offered by
this prospectus supplement have been sold or, if earlier, the
expiration or termination of the Purchase Agreement. We and GHS
each have the right to terminate the Purchase Agreement at any time
upon thirty days notice. In the event of bankruptcy proceedings by
or against us, the Purchase Agreement will automatically terminate
without action of any party.
The above description of the Purchase Agreement is qualified in its
entirety by reference to the Purchase Agreement, which is
incorporated by reference into this prospectus supplement.
RISK FACTORS
Any investment in our
securities involves a high degree of risk, including the risks
described below. Before purchasing our common stock, you should
carefully consider the risk factors set forth below, as well as all
other information contained in this prospectus supplement and the
accompanying prospectus and incorporated by reference, including
our consolidated financial statements and the related notes and the
additional risk factors contained in our most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as any
amendments thereto, as filed with the SEC, before deciding whether
to invest in our common stock. Our business, financial condition
and results of operations could suffer as a result of these risks.
As a result, the trading price of our stock could decline and you
could lose all or part of your investment. The risks discussed
below also include forward-looking statements and our actual
results may differ substantially from those discussed in these
forward-looking statements. See the section entitled
“Forward-Looking Information”.
Risks Related to Our Business
Issues in the use of AI in our offerings may result in
reputational harm or liability.
As with many disruptive innovations, AI presents risks and
challenges that could affect its adoption, and therefore our
business. AI algorithms may be flawed. Datasets may be insufficient
or contain biased information. Inappropriate or controversial data
practices by us or others could impair the acceptance of AI
solutions. These deficiencies could undermine the decisions,
predictions, or analysis AI applications produce, subjecting us to
competitive harm, legal liability, and brand or reputational harm.
Some AI scenarios present ethical issues. If we enable or offer AI
solutions that are controversial because of their impact on human
rights, privacy, employment, or other social issues, we may
experience brand or reputational harm.
We are subject to payment-related risks if customers dispute
or do not pay their invoices, and any decreases or significant
delays in payments could have a material adverse effect on our
business, results of operations and financial condition. These
risks may be heightened as a result of the COVID-19 pandemic
and resulting economic downturn.
We may become involved in disputes with our customers over the
operation of our platform, the terms of our agreements or our
billings for purchases made by them through our platform. In the
past, certain customers have sought to slow their payments to us or
been forced into filing for bankruptcy protection, resulting in
delay or cancelation of their pending payments to us. These
challenges have been exacerbated by the COVID-19 pandemic
and resulting economic impact, and a number of our customers are
experiencing financial difficulties and liquidity constraints. In
certain cases, customers have been unable to timely make payments,
and we have suffered losses. Certain of our contracts with
marketing agencies state that if their customer does not pay the
agency, the agency is not liable to us, and we must seek payment
solely from their customer, a type of arrangement called sequential
liability. Contracting with these agencies, which in some cases
have or may develop higher-risk credit profiles, may subject us to
greater credit risk than if we were to contract directly with the
customer.
If we are unable to collect customers’ fees on a timely basis or at
all, we could incur write-offs for bad debt, which could have a
material adverse effect on our results of operations for the
periods in which the write-offs occur. In the future, bad debt may
exceed reserves for such contingencies, and our bad debt exposure
may increase over time. Any increase in write-offs for bad debt
could have a materially negative effect on our business, financial
condition and operating results. Even if we are not paid by our
customers on time or at all, we may still be obligated to pay for
the inventory we have purchased for our customers’ marketing
campaigns, and consequently, our results of operations and
financial condition would be adversely impacted.
The reliability of some of our product solutions is dependent
on data and software from third-parties and the integrity and
quality of that data and software..
Some of the data and software that we use is licensed from
third-party data suppliers, and we are dependent upon our ability
to obtain necessary data licenses on commercially reasonable terms.
We could suffer material adverse consequences if our data suppliers
were to withhold their data from us. For example, data suppliers
could withhold their data from us if there is a competitive reason
to do so; if we breach our contract with a supplier; if they are
acquired by one of our competitors; if legislation is passed
restricting the use or dissemination of the data they provide; or
if judicial interpretations are issued restricting use of such
data. Additionally, we could terminate relationships with our data
suppliers if they fail to adhere to our data quality standards. If
a substantial number of data suppliers were to withdraw or withhold
their data from us, or if we sever ties with our data suppliers
based on their inability to meet our data standards, our ability to
provide products and services to our clients could be materially
adversely impacted, which could result in decreased revenues.
The reliability of our solutions depends upon the integrity and
quality of the data provided us by our clients and that which we
can license from third party providers. A failure in the integrity
or a reduction in the quality of our data could cause a loss of
customer confidence in our solutions, resulting in harm to our
brand, loss of revenue and exposure to legal claims. We may
experience an increase in risks to the integrity of our database
and quality of our data as we move toward real-time,
non-identifiable, consumer- powered data through our products. We
must continue to invest in our database to improve and maintain the
quality, timeliness and coverage of the data if we are to maintain
our competitive position. Failure to do so could result in a
material adverse effect on our business, growth and revenue
prospects.
Our business practices with respect to data and consumer
protection could give rise to liabilities or reputational harm as a
result of governmental regulation, legal requirements or industry
standards relating to consumer privacy, data protection and
consumer protection.
Federal, state and international laws and regulations govern the
collection, use, retention, sharing and security of data that we
collect. We strive to comply with all applicable laws, regulations,
self-regulatory requirements and legal obligations relating to
privacy, data protection and consumer protection, including those
relating to the use of data for marketing purposes. It is possible,
however, that these requirements may be interpreted and applied in
a manner that is inconsistent from one jurisdiction to another and
may conflict with other rules or our practices. We cannot assure
you that our practices have complied, comply, or will comply fully
with all such laws, regulations, requirements and obligations. Any
failure, or perceived failure, by us to comply with federal, state
or international laws or regulations, including laws and
regulations regulating privacy, data security, marketing
communications or consumer protection, or other policies,
self-regulatory requirements or legal obligations could result in
harm to our reputation, a loss in business, and proceedings or
actions against us by governmental entities, consumers, retailers
or others. We may also be contractually liable to indemnify and
hold harmless performance marketing networks or other third parties
from the costs or consequences of noncompliance with any laws,
regulations, self-regulatory requirements or other legal
obligations relating to privacy, data protection and consumer
protection or any inadvertent or unauthorized use or disclosure of
data that we store or handle as part of operating our business. Any
such proceeding or action, and any related indemnification
obligation, could hurt our reputation, force us to incur
significant expenses in defense of these proceedings, distract our
management, increase our costs of doing business and cause
consumers and retailers to decrease their use of our marketplace,
and may result in the imposition of monetary liability.
Furthermore, the costs of compliance with, and other burdens
imposed by, the data and privacy laws, regulations, standards and
policies that are applicable to the businesses of our clients may
limit the use and adoption of, and reduce the overall demand for,
our products.
A significant breach of the confidentiality of the information we
hold or of the security of our or our customers’, suppliers’, or
other partners’ computer systems could be detrimental to our
business, reputation and results of operations. Our business
requires the storage, transmission and utilization of data.
Although we have security and associated procedures, our databases
may be subject to unauthorized access by third parties. Such third
parties could attempt to gain entry to our systems for the purpose
of stealing data or disrupting the systems. We believe we have
taken appropriate measures to protect our systems from intrusion,
but we cannot be certain that advances in criminal capabilities,
discovery of new vulnerabilities in our systems and attempts to
exploit those vulnerabilities, physical system or facility
break-ins and data thefts or other developments will not compromise
or breach the technology protecting our systems and the information
we possess. Furthermore, we face increasing cyber security risks as
we receive and collect data from new sources, and as we and our
customers continue to develop and operate in cloud-based
information technology environments. In the event that our
protection efforts are unsuccessful, and we experience an
unauthorized disclosure of confidential information or the security
of such information or our systems are compromised, we could suffer
substantial harm. Any breach could result in one or more third
parties obtaining unauthorized access to our customers’ data or our
data, including personally identifiable information, intellectual
property and other confidential business information. Such a
security breach could result in operational disruptions that impair
our ability to meet our clients’ requirements, which could result
in decreased revenues. Also, whether there is an actual or a
perceived breach of our security, our reputation could suffer
irreparable harm, causing our current and prospective clients to
reject our products and services in the future and deterring data
suppliers from supplying us data. Further, we could be forced to
expend significant resources in response to a security breach,
including repairing system damage, increasing cyber security
protection costs by deploying additional personnel and protection
technologies, and litigating and resolving legal claims, all of
which could divert the attention of our management and key
personnel away from our business operations. In any event, a
significant security breach could materially harm our business,
financial condition and operating results.
Significant system disruptions, loss of data center capacity
or interruption of telecommunication links could adversely affect
our business and results of operations.
Our product platform is hosted and managed on Microsoft Azure Cloud
servers and takes full advantage of open standards for processing,
storage, security and big data technology. Significant system
disruptions, loss of data center capacity or interruption of
telecommunication links could adversely affect our business,
results of operations and financial condition. Our business is
heavily dependent upon highly complex data processing capability.
The ability of our platform hosts and managers to protect these
data centers against damage or interruption from fire, flood,
tornadoes, power loss, telecommunications or equipment failure or
other disasters is beyond our control and is critical to our
ability to succeed.
We need to protect our intellectual property or our operating
results may suffer.
Third parties may infringe our intellectual property and we may
suffer competitive injury or expend significant resources enforcing
our rights. As our business is focused on data-driven results and
analytics, we rely heavily on proprietary information technology.
Our proprietary portfolio consists of various intellectual property
including source code, trade secrets, and know-how. The extent to
which such rights can be protected is substantially based on
federal, state and common law rights as well as contractual
restrictions. The steps we have taken to protect our intellectual
property may not prevent the misappropriation of our proprietary
information or deter independent development of similar
technologies by others. If we do not enforce our intellectual
property rights vigorously and successfully, our competitive
position may suffer which could harm our operating results.
We could incur substantial costs and disruption to our
business as a result of any claim of infringement of another
party’s intellectual property rights, which could harm our business
and operating results.
From time to time, third parties may claim that one or more of our
products or services infringe their intellectual property rights.
We analyze and take action in response to such claims on a
case-by-case basis. Any dispute or litigation regarding patents or
other intellectual property could be costly and time-consuming due
to the complexity of our technology and the uncertainty of
intellectual property litigation, which could divert the attention
of our management and key personnel away from our business
operations. A claim of intellectual property infringement could
force us to enter into a costly or restrictive license agreement,
which might not be available under acceptable terms or at all, or
could subject us to significant damages or to an injunction against
development and sale of certain of our products or services.
We may be unable to maintain a competitive technology
advantage in the future.
Our ability to generate revenues is substantially based upon our
proprietary intellectual property that we own and protect through
trade secrets and agreements with our employees to maintain
ownership of any improvements to our intellectual property. Our
ability to generate revenues now and in the future is based upon
maintaining a competitive technology advantage over our
competition. We can provide no assurances that we will be able to
maintain a competitive technology advantage in the future over our
competitors, many of whom have significantly more experience, more
extensive infrastructure and are better capitalized than us.
We may not be able to integrate, maintain and enhance our
advertising solutions to keep pace with technological and market
developments.
The market for digital advertising solutions is characterized by
rapid technological change, evolving industry standards and
frequent introductions of new products and services. To keep pace
with technological developments, satisfy increasing publisher and
advertiser requirements, maintain the attractiveness and
competitiveness of our advertising solutions and ensure
compatibility with evolving industry standards and protocols, we
will need to anticipate and respond to varying product lifecycles,
regularly enhance our current advertising solutions and develop and
introduce new solutions and functionality on a timely basis. This
requires significant investment of financial and other resources.
For example, we will need to invest significant resources into
expanding and developing our platforms in order to maintain a
comprehensive solution. Ad technology platforms and other
technological developments may displace us or introduce an
additional intermediate layer between us and our customers and
digital media properties that could impair our relationships with
those customers.
If we default on our credit obligations, our operations may
be interrupted and our business and financial results could be
adversely affected.
Vendors extend us credit terms for the purchase of advertising
inventory. We currently have outstanding payables to existing
vendors. If we are unable to pay our publishers in a timely
fashion, they may elect to no longer sell us inventory to provide
for sale to advertisers. Also, it may be necessary for us to incur
additional indebtedness to maintain operations of the Company. If
we default on our credit obligations, our lenders and debt
financing holders may, among other things:
|
● |
require repayment of
any outstanding obligations or amounts drawn on our credit
facilities; |
|
|
|
|
● |
stop delivery of
ordered equipment; |
|
|
|
|
● |
discontinue our
ability to acquire inventory that is sold to
advertisers; |
|
|
|
|
● |
require us to accrue
interest at higher rates; or |
|
|
|
|
● |
require us to pay
significant damages. |
If some or all of these events were to occur, our operations may be
interrupted and our ability to fund our operations or obligations,
as well as our business, financial results, and financial
condition, could be adversely affected.
Risks Related to our Common Stock and this Offering
There is a limited existing market for our common stock and
we do not know if a more liquid market for our common stock will
develop to provide you with adequate liquidity.
Prior to this offering, there has been a limited public market for
our common stock as quoted on the OTC Pink, and a more active
trading market for our common stock may not develop or be
maintained following this offering. You may not be able to sell
your shares quickly or at the market price if trading in our
securities is not active. The public offering price for the shares
of common stock will be determined by negotiations between us and
the underwriter and may not be indicative of prices that will
prevail in the trading market. In the absence of an active public
trading market:
|
● |
you may not be able to
resell your shares of common stock at or above the public offering
price; |
|
|
|
|
● |
the market price of
our common stock may experience more price volatility;
and |
|
|
|
|
● |
there may be less
efficiency in carrying out your purchase and sale
orders. |
You may experience immediate and substantial dilution in the
net tangible book value per share of the common stock you purchase
in the offering. In addition, we may issue additional equity or
convertible debt securities in the future, which may result in
additional dilution to you.
The offering price per share in this offering may exceed the net
tangible book value per share of our common stock outstanding as of
September 30, 2021. Assuming that we sell an aggregate of
344,827,586 shares of our common stock for aggregate gross proceeds
of $10,000,000, and after deducting estimated aggregate offering
expenses payable by us, you will experience immediate dilution of
approximately $0.0028 per share, representing the difference
between our pro forma as adjusted net tangible book value per share
as of September 30, 2021 after giving effect to this offering and
the assumed effective offering price. See the section titled
“Dilution” below for a more detailed illustration of the dilution
you would incur if you participate in this offering.
Management will have broad discretion in determining how to
use the proceeds of this offering.
Our management will have
broad discretion over the use of proceeds from this offering, and
we could spend the proceeds from this offering in ways our
stockholders may not agree with or that do not yield a favorable
return, if at all. We currently intend to use the net proceeds from
this offering for general corporate purposes, including general
working capital purposes. If we do not invest or apply the proceeds
of this offering in ways that improve our operating results, we may
fail to achieve expected financial results, which could cause the
market price of our common stock to decrease.
Additional stock offerings in the future may dilute then
existing stockholders’ percentage ownership of our
company.
Given our plans and expectations that we will need additional
capital, we anticipate that we will need to issue additional shares
of common stock or securities convertible or exercisable for shares
of common stock, including convertible preferred stock, convertible
notes, stock options or warrants. The issuance of additional
securities in the future will dilute the percentage ownership of
then existing stockholders.
We have a substantial number of convertible securities
outstanding. The exercise of our outstanding warrants/options and
conversion of our outstanding preferred shares can have a dilutive
effect on our common stock.
We have a substantial number of convertible securities outstanding.
The exercise of our outstanding options and conversion of our
outstanding convertible preferred stock can have a dilutive effect
on our common stock. As of March 23, 2022, we had (i) outstanding
options to purchase approximately 890,733,332 shares of our common
stock at a weighted average exercise price of $0.0093 per shares;
(ii) outstanding warrants to purchase approximately 162,709,169
shares of our common stock at an exercise price of $0.0479; and
(iii) outstanding shares of our Series B, C, D, E, and G Preferred
Stock that, upon conversion without regard to any beneficial
ownership limitations, would provide the holders with an aggregate
of 966,611,711 shares of our common stock. The issuance of shares
of common stock upon exercise of outstanding options and warrant or
conversion of preferred stock could result in substantial dilution
to our stockholders, which may have a negative effect on the price
of our common stock.
FORWARD-LOOKING
INFORMATION
The prospectus and this
prospectus supplement, including the documents that we incorporate
by reference, contain forward-looking statements. These
statements are based on our management’s beliefs and assumptions
and on information currently available to our management.
Forward-looking statements include statements concerning:
|
● |
our possible or
assumed future results of operations; |
|
|
|
|
● |
our business
strategies; |
|
|
|
|
● |
our ability to attract
and retain customers; |
|
|
|
|
● |
our ability to sell
additional products and services to customers; |
|
|
|
|
● |
our cash needs and
financing plans; |
|
|
|
|
● |
our competitive
position; |
|
|
|
|
● |
our industry
environment; |
|
|
|
|
● |
our potential growth
opportunities; |
|
|
|
|
● |
expected technological
advances by us or by third parties and our ability to leverage
them; |
|
|
|
|
● |
the effects of future
regulation; and |
|
|
|
|
● |
the effects of
competition. |
All statements in this prospectus supplement, the prospectus and
the documents and information incorporated by reference in this
prospectus supplement and the documents and information
incorporated by reference in the prospectus that are not historical
facts are forward-looking statements. We may, in some cases, use
terms such as “anticipates,” “believes,” “could,” “estimates,”
“expects,” “intends,” “may,” “plans,” “potential,” “predicts,”
“projects,” “should,” “will,” “would” or similar expressions or the
negative of such items that convey uncertainty of future events or
outcomes to identify forward-looking statements.
You should read the prospectus and this prospectus supplement and
the documents that we reference herein and therein and have filed
as exhibits to the registration statement, of which the prospectus
and this prospectus supplement is part, completely and with the
understanding that our actual future results may be materially
different from what we expect. You should assume that the
information appearing in the prospectus and this prospectus
supplement is accurate as of the date on the front cover of the
prospectus or this prospectus supplement only. Because the risk
factors referred to or incorporated by reference in this prospectus
supplement could cause actual results or outcomes to differ
materially from those expressed in any forward-looking statements
made by us or on our behalf, you should not place undue reliance on
any forward-looking statements. Further, any forward-looking
statement speaks only as of the date on which it is made, and we
undertake no obligation to update any forward-looking statement to
reflect events or circumstances after the date on which the
statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not
possible for us to predict which factors will arise. In addition,
we cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. We qualify all of the information
presented in the prospectus and this prospectus supplement, and
particularly our forward-looking statements, by these cautionary
statements.
USE OF
PROCEEDS
We estimate that the net proceeds from this offering, after
deducting estimated offering expenses payable by us, will be
approximately $9,765,000.
We intend to use the net proceeds from this offering for working
capital and general corporate purposes.
As of the date of this prospectus supplement, we cannot specify
with certainty all of the particular uses of the proceeds from this
offering. We may find it necessary or advisable to use the net
proceeds for other purposes, and we will have broad discretion in
using these proceeds. Investors will be relying on our judgment
regarding the use of the net proceeds from this offering. Pending
the use of proceeds as described above, we plan to invest the net
proceeds that we receive in short-term and intermediate-term
interest-bearing obligations, investment-grade investments,
certificates of deposit or direct or guaranteed obligations of the
U.S. government. We cannot predict whether the invested proceeds
will yield a favorable return.
DILUTION
If you invest in our common stock, your interest will be diluted
immediately to the extent of the difference between the offering
price per share and the as adjusted net tangible book value per
share of our common stock after this offering.
Our net tangible book value as of September 30, 2021 was a surplus
of approximately $2,471,154, or positive $0.0025 per share of
common stock. Net tangible book value per share is determined by
dividing our total tangible assets, less total liabilities, by the
number of our shares of common stock outstanding as of that
respective date.
After giving effect to the sale of an assumed aggregate of
344,827,586 shares of our common stock for aggregate gross proceeds
of $10,000,000 (assuming the sale of the maximum offering amount,
and based on a number of shares equal to 112.5% of $10,000,000
divided by 90% of the closing price of our common stock of $0.0290
on March 28, 2022, for an effective assumed offering price per
share of $0.0290 ) in this offering, and after deducting estimated
offering expenses payable by us, our pro forma as adjusted net
tangible book value as of September 30, 2021 would have been
approximately ($12,471,154 ) million, or approximately ($0.0092 )
per share of our common stock. This represents an immediate
increase in net tangible book value of $0.0068 per share of our
common stock to our existing stockholders and an immediate dilution
in net tangible book value of approximately $0.0028 per share of
our common stock to new investors. The following table illustrates
per share dilution:
The following table illustrates this dilution on a per share
basis:
Assumed effective offering price per
share |
|
$ |
0.0290 |
|
Net tangible book value per share
as of September 30, 2021 |
|
$ |
0.0025 |
|
|
|
|
|
|
Increase in net
tangible book value per share attributable to this offering |
|
$ |
0.0068 |
|
|
|
|
|
|
Pro forma net
tangible book value per share, to give effect to this offering |
|
$ |
0.0092 |
|
Dilution per
share to new investors participating in this offering |
|
$ |
0.0028 |
|
The above discussion and table, prior to adjustments and the pro
forma adjustment, are based on 1,007,953,473 shares of common stock
issued and outstanding as of September 30, 2021 and excludes:
|
● |
450,625,000 shares of
common stock issuable upon conversion of 18,025 outstanding shares
of Series B Preferred Stock; |
|
|
|
|
● |
144,250,000 shares of
common stock issuable upon conversion of 14,425 outstanding shares
of Series C Preferred Stock; |
|
|
|
|
● |
215,052,500 shares of
common stock issuable upon conversion of 86,021 outstanding shares
of Series D Preferred Stock; |
|
|
|
|
● |
20,000,000 shares of
common stock issuable upon conversion of 10,000 outstanding shares
of Series E Preferred Stock; |
|
|
|
|
● |
136,684,211 shares of
common stock issuable upon conversion of 2,597 outstanding shares
of Series G Preferred Stock; |
|
|
|
|
● |
890,733,332 shares of
common stock issuable upon exercise of outstanding stock options,
with a weighted average exercise price of $.0093 per
share; |
|
|
|
|
● |
151,000,000 shares of
common stock issuable upon exercise of common stock warrants, with
an exercise price of $0.0454; and |
|
|
|
|
● |
10,714,286 shares of
common stock issuable upon exercise of common stock warrants, with
an exercise price of $.0875. |
DESCRIPTION OF THE
SECURITIES WE ARE OFFERING
In this offering, we are offering shares of our common stock. The
material terms and provisions of our common stock are described
under the captions “Description of Capital Stock” beginning on page
10 of the accompanying prospectus.
PLAN OF
DISTRIBUTION
We are filing this prospectus supplement to cover the offer and
sale of up to $10,000,000 of shares of our common stock, which we
may sell from time to time in our sole discretion to GHS over the
next year, subject to the conditions and limitations in the
Purchase Agreement.
We entered into the Purchase Agreement with GHS on March 28, 2022.
The Purchase Agreement provides that, upon the terms and subject to
the conditions set forth therein, GHS is committed to purchase an
aggregate of up to $10,000,000 of shares of our common stock over
the one-year term of the Purchase Agreement. See “The
Offering—Purchase Agreement with GHS Investments, LLC.” GHS may be
deemed to be an “underwriter” within the meaning of Section
2(a)(11) of the Securities Act.
The Company has the right, in its sole discretion, subject to the
conditions and limitations in the Purchase Agreement, to direct
GHS, by delivery of a purchase notice from time to time (a
“Purchase Notice”) to purchase (each, a “Purchase”) over the
one-year term of the Purchase Agreement, a minimum of a minimum of
$10,000 and up to a maximum of the lower of: (1) one hundred
percent (100%) of the average daily trading dollar volume of the
Company’s common stock during the ten trading days preceding the
Purchase Date; or (2) one million dollars ($1,000,000), provided
that the parties may agree to waive such limitations. The aggregate
value of Purchase Shares sold to GHS may not exceed $10,000,000.
Each Purchase Notice will set forth the Purchase Price and number
of Purchase Shares in accordance with the terms of the Purchase
Agreement.
The number of Purchase Shares we will issue under each Purchase
will be equal to 112.5% of the Purchase Amount sold under such
Purchase, divided by the Purchase Price per share (as defined in
the Purchase Agreement).
The Purchase Price is defined as the lower of (a) 90% of the lowest
volume weighted average price during the Valuation Period; or (b)
the Closing Price for our common stock on the trading day preceding
the date of the Purchase Notice. The Purchase Price will be subject
to a floor of $.01 per share, at or below which the Company will
not deliver a Purchase Notice. The Valuation Period is the ten
consecutive business days immediately preceding, but not including,
the date a Purchase Notice is delivered. The Company may not
deliver a Purchase Notice prior to five business days from the most
recent receipt by GHS’s broker of Purchase Shares, except as the
parties may otherwise agree.
We estimate our total expenses for this offering, assuming we sell
the maximum offering amount of $10,000,000, will be approximately
$235,000.
This offering will terminate on the date that all shares offered by
this prospectus supplement have been sold or, if earlier, the
expiration or termination of the Purchase Agreement. We and GHS
each have the right to terminate the Purchase Agreement at any time
upon thirty days notice. In the event of bankruptcy proceedings by
or against us, the Purchase Agreement will automatically terminate
without action of any party.
LEGAL
MATTERS
The validity of the securities being offered under this prospectus
by us will be passed upon for us by Sichenzia Ross Ference LLP, New
York, New York.
EXPERTS
The financial statements incorporated by reference into this
prospectus have been so included in reliance on the reports of
M&K CPAs, PLLC, an independent registered public accounting
firm, related to the consolidated financial statements as of
December 31, 2020 and 2019 and for the years then ended, given
on the authority of said firm as experts in auditing and
accounting.
WHERE YOU CAN FIND
MORE INFORMATION
We are subject to the reporting requirements of the Exchange Act
and file annual, quarterly and current reports, and other
information with the SEC. These reports, proxy statements and other
information are available at the SEC’s website at
http://www.sec.gov.
This prospectus supplement and the accompanying prospectus are only
part of a registration statement on Form S-3 that we have filed
with the SEC under the Securities Act and therefore omit certain
information contained in the registration statement. We have also
filed exhibits and schedules with the registration statement that
are excluded from this prospectus supplement and the accompanying
prospectus, and you should refer to the applicable exhibit or
schedule for a complete description of any statement referring to
any contract or other document. The registration statement,
including the exhibits and schedules, without charge, are available
at the SEC’s website.
We also maintain a website at www.cloudcommerce.com, through which
you can access our SEC filings. The information set forth on our
website is not part of this prospectus supplement or the
accompanying prospectus.
INCORPORATION OF
DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” into this
prospectus the information that we file with them, which means that
we can disclose important information to you by referring you to
those documents. The information incorporated by reference is
considered to be part of this prospectus, and information that we
file later with the SEC will automatically update and supersede
this information. The following documents are incorporated by
reference and made a part of this prospectus:
|
● |
our Annual Report on Form 10-K
and Form 10-K/A for the fiscal year ended December 31, 2020
(filed with the SEC on March
15, 2021 and
March 18, 2021, respectively); |
|
● |
Our Quarterly Reports on
Form 10-Q for the quarter ended March 31, 2021 (filed with the
SEC on
May 17, 2021), for the quarter ended June 30, 2021 (filed with
the SEC on
August 16, 2021), and for the quarter ended September 30,
2021 (filed with the SEC on
November 15, 2021); |
|
● |
our Current Reports on Form 8-K filed
with the SEC on
January 11, 2021,
January 15, 2021,
February 2, 2021,
February 9, 2021,
February 22, 2021,
March 8, 2021,
March 22, 2021,
April 19, 2021,
August 6, 2021, October
1, 2021,
October 12, 2021,
October 26, 2021,
November 4, 2021,
December 3, 2021; |
|
● |
The description of our common stock
contained in Exhibit 4.2 to our Annual Report on Form 10-K for
the year ended December 31, 2020; and |
|
● |
all reports and other documents
subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and
15(d) of the Exchange Act after the date of this prospectus and
prior to the termination of this offering. |
Nothing in this prospectus shall be deemed to incorporate
information furnished but not filed with the SEC (including without
limitation, information furnished under Item 2.02 or Item 7.01 of
Form 8-K, and any exhibits relating to such information).
Any statement contained in this prospectus or in a document
incorporated or deemed to be incorporated by, reference in this
prospectus shall be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement
contained herein or in the applicable prospectus supplement or in
any other subsequently filed document which also is or is deemed to
be incorporated by reference modifies or supersedes the statement.
Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this
prospectus.
The information about us contained in this prospectus should be
read together with the information in the documents incorporated by
reference. You may request a copy of any or all of these filings,
at no cost, by writing or telephoning us at: AiAdvertising, Inc.
321 Sixth Street, San Antonio, TX 78215. Our telephone
number is +1-805-964-3313. Information about us is also available
at our website at www.aiadvertising.com However, the
information in our website is not a part of this prospectus and is
not incorporated by reference.
Prospectus

CloudCommerce,
Inc.
$100,000,000
COMMON STOCK
PREFERRED STOCK
WARRANTS
SUBSCRIPTION RIGHTS
DEPOSITARY SHARES
PURCHASE CONTRACTS
UNITS
We may offer and sell from time to time, in one or more series or
issuances and on terms that we will determine at the time of the
offering, any combination of the securities listed below and
described in this prospectus, up to an aggregate amount of
$100,000,000:
|
● |
warrants to purchase our securities; |
|
● |
subscription rights to purchase any of the
foregoing securities; |
|
● |
units
comprised of, or other combinations of, the foregoing
securities. |
We may offer and sell these securities separately or together, in
one or more series or classes and in amounts, at prices and on
terms described in one or more offerings. We may offer securities
through underwriting syndicates managed or co-managed by one or
more underwriters or dealers, through agents or directly to
purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for
that offering. For general information about the distribution of
securities offered, please see “Plan of Distribution” in this
prospectus.
Each time our securities are offered, we will provide a prospectus
supplement containing more specific information about the
particular offering and attach it to this prospectus. The
prospectus supplements may also add, update or change information
contained in this prospectus. This prospectus may not be used to
offer or sell securities without a prospectus supplement which
includes a description of the method and terms of this
offering.
In addition, we have registered for resale by means of separate
prospectus (the “Selling Stockholder Prospectus”) 38,001,563
outstanding shares of common stock held by certain Selling
Stockholders named in the Selling Stockholder Prospectus and up to
10,912,852 shares of common stock issuable upon exercise of
warrants held by the Selling Stockholders. Sales of our securities
registered in this prospectus and in the Selling Stockholder
Prospectus may result in two offerings taking place sequentially or
concurrently, which could affect the price and liquidity of, and
demand for, our securities.
Our common stock is quoted on the OTC Pink market under the symbol
“CLWD.” The last reported sale price of our common stock on OTC
Pink market on February 12, 2021, was $0.1285 per share. On
December 11, 2020, it was $0.006.
During calendar year 2020, our common stock traded at a low of
$0..001 and a high of $0.0163. From the beginning of 2021 through
February 12, 2021, our common stock traded at a low of $0.00596 and
a high of $0.185. We do not believe that this volatility
corresponds to any recent change in our financial condition.
However, our recent launch of an artificial intelligence (AI)
venture focused on using AI to enhance our existing SWARM solution
with the goal of cutting advertising costs, as well as conditions
in the financial markets generally, may have caused or contributed
to this volatility. The stock market in general, and the market for
technology companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of those
companies.
If we decide to seek a listing or qualification for trading of any
preferred stock, warrants, subscriptions rights, depositary shares
or units offered by this prospectus, the related prospectus
supplement will disclose the exchange or market on which the
securities will be listed or traded, if any, or where we have made
an application for listing or trading, if any.
Investing in our securities involves a high degree of risk,
including but not limited to the volatility of our stock price,
which may cause the price of any securities we may offer hereunder
to decline below the initial offering price. See “Risk Factors”
beginning on page 4 and the risk factors in our most recent Annual
Report on Form 10-K, which are incorporated by reference herein, as
well as in any other more recently filed annual, quarterly or
current reports and, if any, in the relevant prospectus supplement.
We urge you to carefully read this prospectus and the accompanying
prospectus supplement, together with the documents we incorporate
by reference, describing the terms of these securities before
investing.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal
offense.
The date of this Prospectus is February 16, 2021.
TABLE OF CONTENTS
ABOUT THIS
PROSPECTUS
This prospectus is part of a registration statement on Form S-3
that we filed with the Securities and Exchange Commission, or SEC,
utilizing a “shelf” registration process. Under this shelf
registration process, we may offer and sell, either individually or
in combination, in one or more offerings, any of the securities
described in this prospectus, for total gross proceeds of up to
$100,000,000. This prospectus provides you with a general
description of the securities we may offer. Each time we offer
securities under this prospectus, we will provide a prospectus
supplement to this prospectus that will contain more specific
information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that
may contain material information relating to these offerings. The
prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or
change any of the information contained in this prospectus or in
the documents that we have incorporated by reference into this
prospectus.
We urge you to read carefully this prospectus, any applicable
prospectus supplement and any free writing prospectuses we have
authorized for use in connection with a specific offering, together
with the information incorporated herein by reference as described
under the heading “Incorporation of Documents by Reference,” before
investing in any of the securities being offered. You should rely
only on the information contained in, or incorporated by reference
into, this prospectus and any applicable prospectus supplement,
along with the information contained in any free writing
prospectuses we have authorized for use in connection with a
specific offering. We have not authorized anyone to provide you
with different or additional information. This prospectus is an
offer to sell only the securities offered hereby, but only under
circumstances and in jurisdictions where it is lawful to do so.
The information appearing in this prospectus, any applicable
prospectus supplement or any related free writing prospectus is
accurate only as of the date on the front of the document and any
information we have incorporated by reference is accurate only as
of the date of the document incorporated by reference, regardless
of the time of delivery of this prospectus, any applicable
prospectus supplement or any related free writing prospectus, or
any sale of a security.
This prospectus contains summaries of certain provisions contained
in some of the documents described herein, but reference is made to
the actual documents for complete information. All of the summaries
are qualified in their entirety by the actual documents. Copies of
some of the documents referred to herein have been filed, will be
filed or will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under the
section entitled “Where You Can Find Additional Information.”
CAUTIONARY NOTE
REGARDING FORWARD LOOKING STATEMENTS
This prospectus and any accompanying prospectus supplement and the
documents incorporated by reference herein may contain forward
looking statements that involve risks and uncertainties. All
statements other than statements of historical fact contained in
this prospectus and any accompanying prospectus supplement and the
documents incorporated by reference herein, including statements
regarding future events, our future financial performance, business
strategy, and plans and objectives of management for future
operations, are forward-looking statements. We have attempted to
identify forward-looking statements by terminology including
“anticipates,” “believes,” “can,” “continue,” “could,” “estimates,”
“expects,” “intends,” “may,” “plans,” “potential,” “predicts,”
“should,” or “will” or the negative of these terms or other
comparable terminology. Although we do not make forward looking
statements unless we believe we have a reasonable basis for doing
so, we cannot guarantee their accuracy. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including the risks outlined under “Risk Factors” or
elsewhere in this prospectus and the documents incorporated by
reference herein, which may cause our or our industry’s actual
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. Moreover, we
operate in a highly regulated, very competitive, and rapidly
changing environment. New risks emerge from time to time and it is
not possible for us to predict all risk factors, nor can we address
the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause our actual results
to differ materially from those contained in any forward-looking
statements.
We have based these forward-looking statements largely on our
current expectations and projections about future events and
financial trends that we believe may affect our financial
condition, results of operations, business strategy, short term and
long term business operations, and financial needs. These
forward-looking statements are subject to certain risks and
uncertainties that could cause our actual results to differ
materially from those reflected in the forward looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to, those discussed in this prospectus, and in
particular, the risks discussed below and under the heading “Risk
Factors” and those discussed in other documents we file with the
Securities and Exchange Commission (the “Commission”). This
prospectus should be read in conjunction with the consolidated
financial statements as of and for the years ended December 31,
2019 and 2018, and as of, and for the three and nine months ended
September 30, 2020 and 2019, and related notes thereto,
incorporated by reference into this prospectus. We undertake no
obligation to revise or publicly release the results of any
revision to these forward-looking statements, except as required by
law. In light of these risks, uncertainties and assumptions, the
forward-looking events and circumstances discussed in this
prospectus may not occur and actual results could differ materially
and adversely from those anticipated or implied in the
forward-looking statement. You should not place undue reliance on
any forward-looking statement, each of which applies only as of the
date of this prospectus. You are advised, however, to consult any
further disclosures we make on related subjects in our reports on
Forms 10-K, 10-Q and 8-K filed with the Commission after the date
of this prospectus.
PROSPECTUS
SUMMARY
This summary highlights selected information contained elsewhere
in this prospectus. This summary does not contain all the
information that you should consider before investing in our
Company. You should carefully read the entire prospectus, including
all documents incorporated by reference herein. In particular,
attention should be directed to our “Risk Factors,” “Information
with Respect to the Company,” “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and the financial
statements and related notes thereto contained herein or otherwise
incorporated by reference hereto, before making an investment
decision.
All references herein to “CloudCommerce,” “we,” “us,” “our,” and
the “Company” mean CloudCommerce, Inc. and its
subsidiaries.
Business Overview
CloudCommerce is a leading provider of digital advertising
solutions. Our flagship solution, SWARM, analyzes a robust mix of
audience data to help businesses find who to talk to, what to say
to them, and how to market to them. We do this by applying advanced
data science, behavioral science, artificial intelligence, and
market research techniques to discover, develop and create custom
audiences for highly targeted digital marketing
campaigns.
SWARM- An Audience Intelligence Solution
SWARM is an end-to-end solution that helps businesses find who to
talk to, what to say to them, and how to motivate them to take
meaningful action. It does this by applying advanced data science,
behavioral science, artificial intelligence, and market research
techniques to discover, develop and create custom audiences for any
business activity. With applications, such as marketing, brand
perception, customer relationship management, human resources
management and operational logistics, SWARM delivers powerful
audience-driven business intelligence to convert opportunities into
business success.
The Problem
Marketers have largely taken a blanket approach to communication.
The same message is often sent across an entire customer audience
with little regard for how different groups of people communicate,
build communities, and develop their purchasing habits. When they
do segment audiences, they tend to use very objective selection
criteria, such as income, geography, education or purchase history
to deduce attitudes or intentions.
However, research has shown that attitudes and intentions are weak
predictors of behavior, which is ultimately what marketers want to
influence and affect. Instead, we believe motivations and
feelings are much better at predicting behavior. But they are also
can be the hardest to deduce from audience data.
The Solution – SWARM
SWARM is a behavioral science approach to audience creation and
communication. It helps marketers probe deep consumer motivations
and triggers, in order to effectively predict and influence their
actions. We believe if marketers can influence action, they can get
people to buy, change the opinion of, or support a particular
brand, business, or person.
There are 4 major products in SWARM:
BUZZ - Behavior Based Market Research
We believe that market research is evolving and that the techniques
being developed today are more sophisticated and backed by strong
data science. Despite these changes, many traditional research
firms have failed to innovate, including: small sample sizes,
survey design bias, improper weighting, and gut intuition sampling
are just some of the issues that plague the industry. BUZZ is
designed with the ability to put a finger on the pulse of the
marketplace in the moment. It does this by deducing attitudes,
emotions, and opinions from various internal and external data
sources such as customer data, social media activity, or micro and
macro trends. We have automated the market research process that we
believe provides a level of statistical depth beyond what
traditional firms can offer.
THE SWARM – Intelligent Audience Building
The core of our solution, and what we believe separates us from
other audience data companies, is our unique approach to audience
building. The concept of ‘personas’ has been around for decades,
but we aim take that general concept to the next level. THE SWARM
was developed to solve not only who to talk to, but also what to
say to them, and how to motivate them to take meaningful action.
Using our proprietary clustering and behavioral analysis
techniques, we believe we are able to create audiences that are
more efficient, targeted, and focused than traditional methods. Our
clustering is designed to not only finds the right people to talk
to, but also the message that motivate them.
HIVE – Redefined Geographic Targeting
Our approach is that conventional geographic audience targeting is
outdated. Arbitrary units of location like counties, cities, DMAs,
and regions were created hundreds of years ago based on land rights
ownership. We believe their use in understanding people’s behavior,
purchase habits, and underlying values is minimal. We try to solve
this by clustering people into granular geographic tribes, called
“Hives.” We define Hives by attributes such as common language
(e.g., colloquialisms), shared experience and narratives (e.g.,
climate, history), and concentrated demography and biology (e.g.,
ethnicity, age). Based on the needs of our clients, we can redraw
the geographic lines based on various Hive selection criteria,
which can make marketing more efficient, business decisions more
intelligent, and growth more plausible.
HONEY – Advanced Reporting and Visualization
We believe advanced audience data analysis technologies are useless
if it doesn’t produce simple, powerful and actionable business
intelligence. HONEY comes with user-friendly reporting and
visualization tools intended to organize and explain all of the
advance data science into a simple to understand format for
decision makers. HONEY is designed to combine the intelligence of
client CRM data with third-party consumer data and targeted market
research to create a powerful foundation for any audience
intelligence solution.
Comprehensive Product Ecosystem
We are constantly striving to help our clients better understand
both their current audience and the larger marketplace. Our team
has developed a series of products intended to challenge the status
quo of how intelligence is done within the marketing industry. Each
of our products can stand alone, but grow more powerful as part of
a larger ecosystem.
Core Services
Together with its wholly-owned subsidiaries, CloudCommerce can
deliver end-to-end marketing solutions through a range of services
and capabilities. SWARM implementations can include some or all of
these capabilities.
Data Propria – Data Analytics
To deliver the highest Return on Investment (“ROI”) for our
customers’ digital marketing campaigns, we utilize sophisticated
data science to identify the correct universes to target relevant
audiences. Our ability to understand and translate data drives
every decision we make. By listening to and analyzing our
customers’ data we are able to make informed decisions that
positively impact our customers’ business. We leverage
industry-best tools to aggregate and visualize data across multiple
sources, and then our data and behavioral scientists segment and
model that data to be deployed in targeted marketing campaigns. We
have data analytics expertise in retail, wholesale, distribution,
logistics, manufacturing, political, and several other
industries.
Parscale Digital – Digital Marketing
We help our customers get their message out, educate their market
and tell their story. We do so creatively and effectively by
deploying powerful call-to-action digital campaigns with national
reach and boosting exposure and validation with coordinated
advertising in print media. Our fully-developed marketing plans are
founded on sound research methodologies, brand audits and
exploration of the competitive landscape. Whether our customer is a
challenger brand, a political candidate, or a well-known household
name, our strategists are skillful at leveraging data and creating
campaigns that move people to make decisions.
Giles Design Bureau – Branding and Creative
Services
We approach branding from a “big picture” perspective, establishing
a strong identity and then building on that to develop a
comprehensive branding program that tells our customer’s story,
articulates what sets our customer apart from their competitors and
establishes our customer in their market.
WebTegrity – Development and Managed Infrastructure
Support
Commerce-focused, user-friendly digital websites and apps elevates
our customer’s marketing position and draw consumers to their
products and services. Our platform-agnostic approach allows us to
architect and build solutions that are the best fit for each
customer. Once the digital properties are built, our experts will
help manage and protect the website or app and provide the
expertise needed to scale the infrastructure needed as our
customer’s business grows.
Growth Strategy
Our goal is to become the leading provider of audience-driven
business intelligence and marketing solutions. Our strategies to
meet this goal include:
|
● |
Automate
our SWARM solution through the development of software that will
allow our customers to self-serve on our platform. |
|
● |
Acquire
or partner with companies that can speed up the automation and
delivery of the SWARM platform. |
|
● |
Continue
to hire top talent in the fields of data science, machine learning,
artificial intelligence, and behavioral science. |
|
● |
Drive
profitable business growth. |
Market for Common Stock
Our common stock is quoted on the OTC Pink market under the symbol
“CLWD.”
Selling Stockholder Registration
We have simultaneously registered for resale by means of the
separate Selling Stockholder Prospectus up to 38,001,563 shares of
our Common Stock, which are outstanding shares held by the Selling
Stockholders (the “Resale Shares”). Before, simultaneous with or
after the offering by us of any our securities described in this
prospectus, the Selling Stockholders may offer any or all of the
Resale Shares. We are registering the Resale Shares pursuant to our
agreement with the holders granting them “piggyback” registration
rights.
Selling Shareholders holding the 38,001,563 Resale Shares have
agreed with us that, until April 21, 2021, they will not sell such
shares in an amount per day greater than the higher of a gross
dollar amount of $150,000 or 10% of the daily dollar volume (as
defined in the agreement) for our common stock, provided that such
restriction shall not apply to any sales of the common stock by the
Selling Stockholder at a price equal to or greater than $0.25 per
share. Nevertheless, the sale of the Resale Shares by the Selling
Stockholders could adversely affect the price and liquidity of, and
demand for, our securities.
Corporate Information
Our principal executive offices are located at 321 Sixth Street,
San Antonio, TX 78215, and our telephone number is +1-805-964-3313.
Our website address is www.cloudcommerce.com. The
information contained therein or connected thereto shall not be
deemed to be incorporated into this prospectus or the registration
statement of which it forms a part. The information on our website
is not part of this prospectus.
RISK
FACTORS
Investing in our securities involves a high degree of risk. Before
making an investment decision, you should consider carefully the
risks, uncertainties and other factors described under the caption
“Risk Factors” and elsewhere in our most recent Annual Report on
Form 10-K, as supplemented and updated by subsequent quarterly
reports on Form 10-Q and current reports on Form 8-K, that we have
filed or will file with the SEC, which are incorporated by
reference into this prospectus.
Our business, affairs, prospects, assets, financial condition,
results of operations and cash flows could be materially and
adversely affected by these risks. For more information about our
SEC filings, please see “Where You Can Find More Information.”
The following additional risks could affect an investment in the
securities we may offer pursuant to this prospectus.
The trading price of our common stock may to continue to
be volatile.
The trading price of our common stock has been highly volatile and
could continue to be subject to wide fluctuations in response to
various factors, some of which are beyond our control. During
calendar year 2020, our common stock traded at a low of $0..001 and
a high of $0.0163. From the beginning of 2021 through February 12,
2021, our common stock traded at a low of $0.00596 and a high of
$0.185.
We do not believe that this volatility corresponds to any recent
change in our financial condition. However, our recent launch of an
artificial intelligence (AI) venture focused on using AI to enhance
our existing SWARM solution with the goal of cutting advertising
costs, as well as conditions in the financial markets generally,
may have caused or contributed to this volatility.
The stock market in general, and the market for technology
companies in particular, has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to
the operating performance of those companies. Public perception and
other factors outside of our control may additionally impact the
stock price of companies like us that garner a disproportionate
degree of public attention, regardless of actual operating
performance.
As a result of this volatility, our securities could experience
rapid and substantial decreases in price, and you may be able to
sell securities you purchase under this prospectus only at a
substantial loss to the initial offering price.
Some, but not all, of the factors that may cause the market price
of our common stock to fluctuate include:
|
● |
fluctuations in our quarterly or
annual financial results or the quarterly or annual financial
results of companies perceived to be similar to us or relevant for
our business; |
|
● |
changes in estimates of our
financial results or recommendations by securities
analysts; |
|
● |
failure
of our products to achieve or maintain market
acceptance; |
|
● |
changes
in market valuations of similar or relevant companies; |
|
● |
success
of competitive service offerings or technologies; |
|
● |
changes
in our capital structure, such as the issuance of securities or the
incurrence of debt; |
|
● |
announcements by us or by our competitors of
significant services, contracts, acquisitions or strategic
alliances; |
|
● |
regulatory developments in the United States,
foreign countries, or both; |
|
● |
additions
or departures of key personnel; |
|
● |
investors’ general perceptions; and |
|
● |
changes
in general economic, industry or market conditions. |
In addition, if the market for technology stocks, or the stock
market in general, experiences a loss of investor confidence, the
trading price of our common stock could decline for reasons
unrelated to our business, financial condition, or results of
operations. Further, in the past, following periods of volatility
in the overall market and the market price of a particular
company’s securities, securities class action litigation has often
been instituted against these companies. If any of the foregoing
occurs, it could cause our stock price to fall and may expose us to
lawsuits that, even if unsuccessful, could be costly to defend and
a distraction to management.
[A possible “short squeeze” due to a sudden increase in demand
of our common stock that largely exceeds supply may lead to
additional price volatility.
Historically there has not been a large short position in our
common stock. However, in the future investors may purchase
shares of our common stock to hedge existing exposure or to
speculate on the price of our common stock. Speculation on the
price of our common stock may involve long and short exposures. To
the extent an aggregate short exposure in our common stock becomes
significant, investors with short exposure may have to pay a
premium to purchase shares for delivery to share lenders at times
if and when the price of our common stock increases significantly,
particularly over a short period of time. Those purchases may in
turn, dramatically increase the price of our common stock. This is
often referred to as a “short squeeze.” A short squeeze could lead
to volatile price movements in our common stock that are not
directly correlated to our business prospects, financial
performance or other traditional measures of value for the Company
or its common stock.]
The number of shares of common stock we may offer (or underlying
other securities we may offer) hereunder is significant relative to
the number of shares currently outstanding, and if we offer and
sell a significant number of such securities, it could result in a
decline in the price of our securities.
At the price of our common stock as of the date of this prospectus,
the $100 million of securities we may offer under this prospectus,
in common stock or equivalents, if offered and sold in its
entirety, would represent more than the number of shares of common
stock we currently have outstanding. If we sell a large number of
such securities at one time or over a short period of time, our
securities could experience a substantial decrease in price, and
you may be able to sell securities you purchase under this
prospectus only at a substantial loss to the initial offering
price.
Additional stock offerings in the future may dilute
then-existing shareholders’ percentage ownership of the
Company.
Given our plans and expectations that we will need additional
capital in the future, we anticipate that we will need to issue
additional shares of common stock or securities convertible or
exercisable for shares of common stock, including convertible
preferred stock, convertible notes, stock options or warrants. The
issuance of additional securities in the future will dilute the
percentage ownership and potentially voting power of then current
stockholders and could negatively impact the price of our common
stock and other securities.
USE OF
PROCEEDS
Unless otherwise indicated in a prospectus supplement, we intend to
use the net proceeds from these sales for working capital and
general corporate purposes, which includes, without limitation,
further development of our SWARM advertising platform, investing in
or acquiring companies that are synergistic with or complimentary
to our technologies, licensing activities related to our current
and future product candidates and working capital, the development
of emerging technologies, investing in or acquiring companies that
are developing emerging technologies, licensing activities, or the
acquisition of other businesses. The amounts and timing of these
expenditures will depend on numerous factors, including the
development of our current business initiatives.
PLAN OF
DISTRIBUTION
We may sell the securities from time to time to or through
underwriters or dealers, through agents, or directly to one or more
purchasers. A distribution of the securities offered by this
prospectus may also be effected through the issuance of derivative
securities, including without limitation, warrants, rights to
purchase and subscriptions. In addition, the manner in which we may
sell some or all of the securities covered by this prospectus
includes, without limitation, through:
|
● |
a block
trade in which a broker-dealer will attempt to sell as agent, but
may position or resell a portion of the block, as principal, in
order to facilitate the transaction; |
|
|
|
|
● |
purchases
by a broker-dealer, as principal, and resale by the broker-dealer
for its account; or |
|
|
|
|
● |
ordinary
brokerage transactions and transactions in which a broker solicits
purchasers. |
A prospectus supplement or supplements with respect to each series
of securities will describe the terms of the offering, including,
to the extent applicable:
|
● |
the terms of the
offering; |
|
|
|
|
● |
the name or names of the
underwriters or agents and the amounts of securities underwritten
or purchased by each of them, if any; |
|
|
|
|
● |
the public offering price or
purchase price of the securities or other consideration therefor,
and the proceeds to be received by us from the sale; |
|
|
|
|
● |
any delayed delivery
requirements; |
|
|
|
|
● |
any over-allotment options under
which underwriters may purchase additional securities from
us; |
|
|
|
|
● |
any underwriting discounts or
agency fees and other items constituting underwriters’ or agents’
compensation; |
|
|
|
|
● |
any discounts or concessions
allowed or re-allowed or paid to dealers; and |
|
|
|
|
● |
any securities exchange or market
on which the securities may be listed or quoted. |
The offer and sale of the securities described in this prospectus
by us, the underwriters or the third parties described above may be
effected from time to time in one or more transactions, including
privately negotiated transactions, initially at a fixed price to be
set forth in the applicable pricing supplement. If and
when our common stock is quoted on the OTCQB or OTCQX Market
of OTC Markets, Inc., or a national securities exchange (of which
there can be no assurance), then the securities described in this
prospectus may be offered and sold either:
|
● |
at fixed price or prices, which
may be changed; |
|
|
|
|
● |
in an “at the market” offering
within the meaning of Rule 415(a)(4) of the Securities
Act; |
|
|
|
|
● |
at prices related to such
prevailing market prices; or |
|
|
|
|
● |
at negotiated prices. |
Only underwriters named in the prospectus supplement will be
underwriters of the securities offered by the prospectus
supplement.
Underwriters and Agents; Direct Sales
If underwriters are used in a sale, they will acquire the offered
securities for their own account and may resell the offered
securities from time to time in one or more transactions, including
negotiated transactions, at a fixed public offering price or at
varying prices determined at the time of sale. We may offer the
securities to the public through underwriting syndicates
represented by managing underwriters or by underwriters without a
syndicate.
Unless the prospectus supplement states otherwise, the obligations
of the underwriters to purchase the securities will be subject to
the conditions set forth in the applicable underwriting agreement.
Subject to certain conditions, the underwriters will be obligated
to purchase all of the securities offered by the prospectus
supplement, other than securities covered by any over-allotment
option. Any public offering price and any discounts or concessions
allowed or re-allowed or paid to dealers may change from time to
time. We may use underwriters with whom we have a material
relationship. We will describe in the prospectus supplement, naming
the underwriter, the nature of any such relationship.
We may sell securities directly or through agents we designate from
time to time. We will name any agent involved in the offering and
sale of securities, and we will describe any commissions we will
pay the agent in the prospectus supplement. Unless the prospectus
supplement states otherwise, our agent will act on a best-efforts
basis for the period of its appointment.
We may authorize agents or underwriters to solicit offers by
certain types of institutional investors to purchase securities
from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for
payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we
must pay for solicitation of these contracts in the prospectus
supplement.
Dealers
We may sell the offered securities to dealers as principals. The
dealer may then resell such securities to the public either at
varying prices to be determined by the dealer or at a fixed
offering price agreed to with us at the time of resale.
Institutional Purchasers
We may authorize agents, dealers or underwriters to solicit certain
institutional investors to purchase offered securities on a delayed
delivery basis pursuant to delayed delivery contracts providing for
payment and delivery on a specified future date. The applicable
prospectus supplement or other offering materials, as the case may
be, will provide the details of any such arrangement, including the
offering price and commissions payable on the solicitations.
We will enter into such delayed contracts only with institutional
purchasers that we approve. These institutions may include
commercial and savings banks, insurance companies, pension funds,
investment companies and educational and charitable
institutions.
Indemnification; Other Relationships
We may provide agents, underwriters, dealers and remarketing firms
with indemnification against certain civil liabilities, including
liabilities under the Securities Act, or contribution with respect
to payments that the agents or underwriters may make with respect
to these liabilities. Agents, underwriters, dealers and remarketing
firms, and their affiliates, may engage in transactions with, or
perform services for, us in the ordinary course of business. This
includes commercial banking and investment banking
transactions.
Market-Making; Stabilization and Other Transactions
There is currently no market for any of the offered securities,
other than our common stock, which is quoted on the OTC Pink
market. If the offered securities are traded after their initial
issuance, they may trade at a discount from their initial offering
price, depending upon prevailing interest rates, the market for
similar securities and other factors. While it is possible that an
underwriter could inform us that it intends to make a market in the
offered securities, such underwriter would not be obligated to do
so, and any such market-making could be discontinued at any time
without notice. Therefore, no assurance can be given as to whether
an active trading market will develop for the offered securities.
We have no current plans for listing of the preferred stock,
warrants or subscription rights on any securities exchange or
quotation system; any such listing with respect to any particular
preferred stock, warrants or subscription rights will be described
in the applicable prospectus supplement or other offering
materials, as the case may be.
Any underwriter may engage in over-allotment, stabilizing
transactions, short-covering transactions and penalty bids in
accordance with Regulation M under the Securities Exchange Act of
1934, as amended, or the Exchange Act. Over-allotment involves
sales in excess of the offering size, which create a short
position. Stabilizing transactions permit bids to purchase the
underlying security so long as the stabilizing bids do not exceed a
specified maximum price. Syndicate-covering or other short-covering
transactions involve purchases of the securities, either through
exercise of the over-allotment option or in the open market after
the distribution is completed, to cover short positions. Penalty
bids permit the underwriters to reclaim a selling concession from a
dealer when the securities originally sold by the dealer are
purchased in a stabilizing or covering transaction to cover short
positions. Those activities may cause the price of the securities
to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time.
Any underwriters or agents that are qualified market makers on the
OTC Pink market may engage in passive market making transactions in
our common stock on the OTC Pink market in accordance with
Regulation M under the Exchange Act, during the business day prior
to the pricing of the offering, before the commencement of offers
or sales of our common stock. Passive market makers must comply
with applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker must
display its bid at a price not in excess of the highest independent
bid for such security; if all independent bids are lowered below
the passive market maker’s bid, however, the passive market maker’s
bid must then be lowered when certain purchase limits are exceeded.
Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in
the open market and, if commenced, may be discontinued at any
time.
Fees and Commissions
If 5% or more of the net proceeds of any offering of securities
made under this prospectus will be received by a FINRA member
participating in the offering or affiliates or associated persons
of such FINRA member, the offering will be conducted in accordance
with FINRA Rule 5121.
DESCRIPTION OF
SECURITIES WE MAY OFFER
General
This prospectus describes the general terms of our capital stock.
The following description is not complete and may not contain all
the information you should consider before investing in our capital
stock. For a more detailed description of these securities, you
should read the applicable provisions of Nevada law and our amended
and restated certificate of incorporation, referred to herein as
our certificate of incorporation, and our amended and restated
bylaws, referred to herein as our bylaws. When we offer to sell a
particular series of these securities, we will describe the
specific terms of the series in a supplement to this prospectus.
Accordingly, for a description of the terms of any series of
securities, you must refer to both the prospectus supplement
relating to that series and the description of the securities
described in this prospectus. To the extent the information
contained in the prospectus supplement differs from this summary
description, you should rely on the information in the prospectus
supplement.
We, directly or through agents, dealers or underwriters designated
from time to time, may offer, issue and sell, together or
separately, up to $250,000,000 in the aggregate of:
|
● |
common stock; |
|
|
|
|
● |
preferred stock; |
|
|
|
|
● |
warrants to purchase our
securities; |
|
|
|
|
● |
subscription rights to purchase
our securities; |
|
|
|
|
● |
depositary shares; |
|
|
|
|
● |
purchase contracts;
or |
|
|
|
|
● |
units comprised of, or other
combinations of, the foregoing securities. |
The preferred stock may also be exchangeable for and/or convertible
into shares of common stock, another series of preferred stock or
other securities that may be sold by us pursuant to this prospectus
or any combination of the foregoing. When a particular series of
securities is offered, a supplement to this prospectus will be
delivered with this prospectus, which will set forth the terms of
the offering and sale of the offered securities.
Authorized Capital Stock; Issued and Outstanding Capital
Stock
We have authorized 2,005,000,000 shares of capital stock, par value
$0.001 per share, of which 2,000,000,000 are shares of common stock
and 5,000,000 are shares of preferred stock, 10,000 of which are
designated Series A Preferred Stock, 25,000 of which are designated
as Series B Preferred Stock, 25,000 of which are designated as
Series C Preferred Stock, 90,000 of which are designated as Series
D Preferred Stock, 10,000 of which are designated as Series E
Preferred Stock, 800,000 of which are designated as Series F
Preferred Stock, and 2,600 of which are designated as Series G
Preferred Stock. As of January 20, 2021, there were 702,253,178
shares of common stock issued and outstanding, 10,000 shares of
Series A Preferred Stock outstanding, 18,025 shares of Series B
Preferred Stock outstanding, 14,425 shares of Series C Preferred
Stock outstanding, 90,000 shares of Series D Preferred Stock
outstanding, 10,000 shares of Series E Preferred Stock outstanding,
2,413 shares of Series F Preferred Stock outstanding, and 2,597
shares of Series G Preferred Stock outstanding. The authorized and
unissued shares of common stock and the authorized and undesignated
shares of preferred stock are available for issuance without
further action by our stockholders, unless such action is required
by applicable law or the rules of any stock exchange on which our
securities may be listed. Unless approval of our stockholders is so
required, our board of directors does not intend to seek
stockholder approval for the issuance and sale of our common stock
or preferred stock.
Common
Stock
The holders of our common stock are entitled to one vote per share.
Our certificate of incorporation does not provide for cumulative
voting. At each annual meeting of stockholders, directors are
elected for a term of office to expire at the next succeeding
annual meeting of stockholders. The holders of our common stock are
entitled to receive ratably such dividends, if any, as may be
declared by our board of directors out of legally available funds.
However, the current policy of our board of directors is to retain
earnings, if any, for operations and growth. Upon liquidation,
dissolution or winding-up, the holders of our common stock are
entitled to share ratably in all assets that are legally available
for distribution. The holders of our common stock have no
preemptive, subscription or conversion rights and there are no
redemption or sinking fund provisions applicable to the common
stock. The rights, preferences and privileges of holders of our
common stock are subject to, and may be adversely affected by, the
rights of the holders of any series of preferred stock, which may
be designated solely by action of our board of directors and issued
in the future.
As of January 20, 2021, 702,253,178 shares of common stock were
outstanding.
As of January 20, 2021, we had options to purchase 821,675,799
shares of common stock that are outstanding, with a weighted
average exercise price of $0.0068, of which 247,804,566 were then
exercisable.
We also have warrants to purchase common stock that are
outstanding, which are described below.
As of the date of this prospectus, we have no convertible
promissory notes outstanding.
Preferred
Stock
Outstanding Preferred Stock
Series A Preferred
The Company has designated 10,000 shares of its preferred stock as
Series A Preferred Stock. Each share of Series A Preferred Stock is
convertible into 10,000 shares of the Company’s common stock. The
holders of outstanding shares of Series A Preferred Stock are
entitled to receive dividends, payable quarterly, out of any assets
of the Corporation legally available therefor, at the rate of $8
per share annually, payable in preference and priority to any
payment of any dividend on the common stock. As of September 30,
2020, the Company has 10,000 shares of Series A Preferred Stock
outstanding. During the nine months ended September 30, 2020
and 2019, we paid dividends of $20,000 and $20,000, respectively,
to the holders of Series A Preferred stock. As of September 30,
2020, the balance owed on the Series A Preferred stock dividend was
$120,000.
Series B Preferred
The Company has designated 25,000 shares of its preferred stock as
Series B Preferred Stock. Each share of Series B Preferred Stock
has a stated value of $100. The Series B Preferred Stock is
convertible into shares of the Company's common stock in amount
determined by dividing the stated value by a conversion price of
$0.004 per share. The Series B Preferred Stock does not have voting
rights except as required by law and with respect to certain
protective provisions set forth in the Certificate of Designation
of Series B Preferred Stock. As of September 30, 2020, the Company
has 18,025 shares of Series B Preferred Stock outstanding.
Series C Preferred
The Company has designated 25,000 shares of its preferred stock as
Series C Preferred Stock. Each share of Series C Preferred Stock
has a stated value of $100. The Series C Preferred Stock is
convertible into shares of the Company's common stock by dividing
the stated value by a conversion price of $0.01 per share. The
Series C Preferred Stock does not have voting rights except as
required by law and with respect to certain protective provisions
set forth in the Certificate of Designation of Series C Preferred
Stock. As of September 30, 2020, the Company has 14,425 shares of
Series C Preferred Stock outstanding.
Series D Preferred
The Company has designated 90,000 shares of its preferred stock as
Series D Preferred Stock. Each share of Series D Preferred Stock
has a stated value of $100. The Series D Preferred Stock is
convertible into common stock at a ratio of 2,500 shares of common
stock per share of preferred stock, and pays a quarterly dividend,
calculated as (1/90,000) x (5% of the Adjusted Gross Revenue) of
the Company’s subsidiary Parscale Digital. Adjusted Gross
Revenue shall mean the top line gross revenue of Parscale Digital,
as calculated under GAAP (generally accepted accounting principles)
less any reselling revenue attributed to third party advertising
products or service, such as, but not limited to, search engine
keyword campaign fees, social media campaign fees, radio or
television advertising fees, and the like. The Series D Preferred
Stock does not have voting rights except as required by law and
with respect to certain protective provisions set forth in the
Certificate of Designation of Series D Preferred Stock. As of
September 30, 2020, the Company had 90,000 shares of Series D
Preferred Stock outstanding. During the nine months
ended September 30, 2020, and 2019, we paid dividends of zero,
and zero respectively, to the holders of Series D Preferred stock.
As of September 30, 2020, the balance owed on the Series D
Preferred stock dividend was $237,664, $12,116 of which relates to
the quarter ended September 30, 2020.
Series E Preferred
The Company has designated 10,000 shares of its preferred stock as
Series E Preferred Stock. Each share of Series E Preferred Stock
has a stated value of $100. The Series E Preferred Stock is
convertible into shares of the Company's common stock in an amount
determined by dividing the stated value by a conversion price of
$0.05 per share. The Series E Preferred Stock does not have voting
rights except as required by law and with respect to certain
protective provisions set forth in the Certificate of Designation
of Series E Preferred Stock. As of September 30, 2020, the Company
has 10,000 shares of Series E Preferred Stock outstanding.
Series F Preferred
The Company has designated 800,000 shares of its preferred stock as
Series F Preferred Stock. Each share of Series F Preferred Stock
has a stated value of $25. The Series F Preferred Stock is not
convertible into common stock. The holders of outstanding shares of
Series F Preferred Stock are entitled to receive dividends, at the
annual rate of 10%, payable monthly, payable in preference and
priority to any payment of any dividend on the Company’s common
stock. The Series F Preferred Stock does have voting rights, except
as required by law and with respect to certain protective
provisions set forth in the Certificate of Designation. To the
extent it may lawfully do so, the Company may, in its sole
discretion, after the first anniversary of the original issuance
date of the Series F Preferred Stock, redeem any or all of the then
outstanding shares of Series F Preferred Stock at a redemption
price of $25 per share plus any accrued but unpaid dividends. The
Series F Preferred Stock is being offered in connection with the
Company’s offering under Regulation A under the Securities Act of
1933, as amended. As of September 30, 2020, the Company had 2,413
shares of Series F Preferred Stock outstanding.
Series G Preferred
On February 6, 2020, the Company designated 2,600 shares of its
preferred stock as Series G Preferred Stock. Each share of Series G
Preferred Stock has a stated value of $100. The Series G Preferred
Stock is convertible into shares of the Company's common stock in
an amount determined by dividing the stated value by a conversion
price of $0.0019 per share. The Series G Preferred Stock does not
have voting rights except as required by law and with respect to
certain protective provisions set forth in the Certificate of
Designation of Series G Preferred Stock. As of September 30, 2020,
the Company had 2,597 shares of Series G Preferred Stock
outstanding.
Other Series of Preferred Stock We May Issue
The board of directors is authorized, subject to any limitations
prescribed by law, without further vote or action by our
stockholders, to issue from time to time shares of preferred stock
in one or more series. Each such series of preferred stock shall
have such number of shares, designations, preferences, voting
powers, qualifications and special or relative rights or privileges
as determined by our board of directors, which may include, among
others, dividend rights, voting rights, liquidation preferences,
conversion rights and preemptive rights. Issuance of preferred
stock by our board of directors may result in such shares having
dividend and/or liquidation preferences senior to the rights of the
holders of our common stock and could dilute the voting rights of
the holders of our common stock.
Prior to the issuance of shares of each series of preferred stock,
our board of directors is required by the Nevada Revised Law and
our amended and restated certificate of incorporation to adopt
resolutions and file a certificate of designations with the
Secretary of State of the State of Nevada, which fixes for each
class or series the designations, powers, preferences, rights,
qualifications, limitations and restrictions. We will file as an
exhibit to the registration statement of which this prospectus is a
part, or will incorporate by reference from a current report on
Form 8-K that we file with the Commission, the form of any
certificate of designations for the series of preferred stock we
are offering before the issuance of the related series of preferred
stock. The prospectus supplement relating to any preferred stock
that we may offer will contain the specific terms of the class or
series and of the offering, which terms may include the
following:
|
● |
the title and stated
value; |
|
|
|
|
● |
the number of shares we are
offering; |
|
|
|
|
● |
the offering price; |
|
|
|
|
● |
the number of shares constituting
that series, which number may be increased or decreased (but not
below the number of shares then outstanding) from time to time by
action of our board of directors; |
|
|
|
|
● |
the dividend rate and the manner
and frequency of payment of dividends on the shares of that series,
whether dividends will be cumulative, and, if so, from which
date; |
|
|
|
|
● |
whether that series will have
voting rights, in addition to any voting rights provided by law,
and, if so, the terms of such voting rights; |
|
|
|
|
● |
whether that series will have
conversion privileges, and, if so, the terms and conditions of such
conversion, including provision for adjustment of the conversion
rate in such events as our board of directors may
determine; |
|
|
|
|
● |
whether or not the shares of that
series will be redeemable, and, if so, the terms and conditions of
such redemption; |
|
|
|
|
● |
whether that series will have a
sinking fund for the redemption or purchase of shares of that
series, and, if so, the terms and amount of such sinking
fund; |
|
|
|
|
● |
whether or not the shares of the
series will have priority over or be on a parity with or be junior
to the shares of any other series or class in any
respect; |
|
|
|
|
● |
the rights of the shares of that
series in the event of voluntary or involuntary liquidation,
dissolution or winding up of the corporation, and the relative
rights or priority, if any, of payment of shares of that
series; |
|
|
|
|
● |
preemptive rights, if
any; |
|
|
|
|
● |
restrictions on transfer, sale or
other assignment, if any; |
|
|
|
|
● |
whether interests in the
preferred stock will be represented by depositary
shares; |
|
|
|
|
● |
a discussion of any material or
special United States federal income tax considerations applicable
to the preferred stock; |
|
|
|
|
● |
any limitations on issuance of
any class or series of preferred stock ranking senior to or on a
parity with the series of preferred stock as to dividend rights and
rights if we liquidate, dissolve or wind up our affairs;
and |
|
|
|
|
● |
any other relative rights,
preferences and limitations of that series. |
Once designated by our board of directors, each series of preferred
stock may have specific financial and other terms that will be
described in a prospectus supplement. The description of the
preferred stock that is set forth in any prospectus supplement is
not complete without reference to the documents that govern the
preferred stock. These include our amended and restated certificate
of incorporation and any certificates of designation that our board
of directors may adopt.
All shares of our preferred stock will, when issued, be fully paid
and non-assessable, including shares of our preferred stock issued
upon the exercise of preferred stock warrants or subscription
rights, if any.
Our board of directors may authorize the issuance of preferred
stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of our common
stock. Preferred stock could be issued quickly with terms designed
to delay or prevent a change in control of our Company or make
removal of management more difficult. Additionally, the issuance of
preferred stock could have the effect of decreasing the market
price of our common stock.
Although our board of directors has no intention at the present
time of doing so, it could authorize the issuance of a series of
preferred stock that could, depending on the terms of such series,
impede the completion of a merger, tender offer or other takeover
attempt.
Warrants
We may issue warrants to purchase our securities or other rights,
including rights to receive payment in cash or securities based on
the value, rate or price of one or more specified commodities,
currencies, securities or indices, or any combination of the
foregoing. Warrants may be issued independently or together with
any other securities that may be sold by us pursuant to this
prospectus or any combination of the foregoing and may be attached
to, or separate from, such securities. To the extent warrants that
we issue are to be publicly-traded, each series of such warrants
will be issued under a separate warrant agreement to be entered
into between us and a warrant agent.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from a
current report on Form 8-K that we file with the Commission, forms
of the warrant and warrant agreement, if any. The prospectus
supplement relating to any warrants that we may offer will contain
the specific terms of the warrants and a description of the
material provisions of the applicable warrant agreement, if any.
These terms may include the following:
|
● |
the title of the
warrants; |
|
|
|
|
● |
the aggregate number of
warrants; |
|
|
|
|
● |
the price or prices at which the
warrants will be offered; |
|
|
|
|
● |
the designation, amount and terms
of the securities or other rights for which the warrants are
exercisable; |
|
|
|
|
● |
the designation and terms of the
other securities, if any, with which the warrants are to be issued
and the number of warrants issued with each other
security; |
|
|
|
|
● |
if applicable, the date on and
after which the warrants and the related securities will be
separately transferable; |
|
|
|
|
● |
the price or prices at which the
securities or other rights purchasable upon exercise of the
warrants may be purchased; |
|
|
|
|
● |
any provisions for adjustment of
the number or amount of securities receivable upon exercise of the
warrants or the exercise price of the warrants; |
|
|
|
|
● |
the manner of exercise of the
warrants, including any cashless exercise rights; |
|
|
|
|
● |
the terms of any rights of us to
redeem or call the warrants; |
|
● |
the identities of any warrant
agent and any calculation or other agent for the
warrants; |
|
|
|
|
● |
a discussion of any material U.S.
federal income tax considerations applicable to the exercise of the
warrants; |
|
|
|
|
● |
the date on which the right to
exercise the warrants will commence, and the date on which the
right will expire; |
|
|
|
|
● |
If any, the maximum or minimum
number of warrants that may be exercised at any time; |
|
|
|
|
● |
information with respect to
book-entry procedures, if any; and |
|
|
|
|
● |
any other terms of the warrants,
including terms, procedures and limitations relating to the
exchange and exercise of the warrants. |
Exercise of Warrants. Each warrant will entitle the holder
of warrants to purchase the amount of securities or other rights,
at the exercise price stated or determinable in the prospectus
supplement for the warrants. Warrants may be exercised at any time
up to the close of business on the expiration date shown in the
applicable prospectus supplement, unless otherwise specified in
such prospectus supplement. After the close of business on the
expiration date, if applicable, unexercised warrants will become
void. Warrants may be exercised in the manner described in the
applicable prospectus supplement. When the warrant holder makes the
payment and properly completes and signs the warrant certificate at
the corporate trust office of the warrant agent, if any, or any
other office indicated in the prospectus supplement, we will, as
soon as possible, forward the securities or other rights that the
warrant holder has purchased. If the warrant holder exercises less
than all of the warrants represented by the warrant certificate, we
will issue a new warrant certificate for the remaining
warrants.
Enforceability of Rights By Holders of Warrants. Any warrant
agent will act solely as our agent under the applicable warrant
agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or
trust company may act as warrant agent for more than one issue of
warrants. A warrant agent will have no duty or responsibility in
case of any default by us under the applicable warrant agreement or
warrant, including any duty or responsibility to initiate any
proceedings at law or otherwise, or to make any demand upon us. Any
holder of a warrant may, without the consent of the related warrant
agent or the holder of any other warrant, enforce by appropriate
legal action the holder’s right to exercise, and receive the
securities purchasable upon exercise of, its warrants in accordance
with their terms.
Warrant Agreement Will Not Be Qualified Under Trust Indenture
Act. No warrant agreement will be qualified as an indenture,
and no warrant agent will be required to qualify as a trustee,
under the Trust Indenture Act. Therefore, holders of warrants
issued under a warrant agreement will not have the protection of
the Trust Indenture Act with respect to their warrants.
Outstanding Warrants
As of January 20, 2021, we had outstanding warrants to purchase
20,912,852 shares of common stock with a weighted average exercise
price of $0.0067 per share, all of which are currently exercisable,
but in some cases subject to a customary 4.99% beneficial ownership
“blocker” provisions. Certain warrants may be exercised on a
cashless “net exercise” basis under certain circumstances.
Subscription
Rights
We may issue rights to purchase our securities. The rights may or
may not be transferable by the persons purchasing or receiving the
rights. In connection with any rights offering, we may enter into a
standby underwriting or other arrangement with one or more
underwriters or other persons pursuant to which such underwriters
or other persons would purchase any offered securities remaining
unsubscribed for after such rights offering. In connection with a
rights offering to holders of our capital stock a prospectus
supplement will be distributed to such holders on the record date
for receiving rights in the rights offering set by us.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from a
current report on Form 8-K that we file with the Commission, forms
of the subscription rights, standby underwriting agreement or other
agreements, if any. The prospectus supplement relating to any
rights that we offer will include specific terms relating to the
offering, including, among other matters:
|
● |
the date of determining the
security holders entitled to the rights distribution; |
|
|
|
|
● |
the aggregate number of rights
issued and the aggregate amount of securities purchasable upon
exercise of the rights; |
|
|
|
|
● |
the exercise price; |
|
|
|
|
● |
the aggregate number of rights to
be issued; |
|
|
|
|
● |
the date, if any, on and after
which the rights will be separately transferable; |
|
|
|
|
● |
the conditions to completion of
the rights offering; |
|
|
|
|
● |
the date on which the right to
exercise the rights will commence and the date on which the rights
will expire; |
|
|
|
|
● |
any applicable federal income tax
considerations; and |
|
|
|
|
● |
any other terms of the rights,
including terms, procedures and limitations relating to the
distribution, exchange and exercise of the rights. |
Each right would entitle the holder of the rights to purchase the
principal amount of securities at the exercise price set forth in
the applicable prospectus supplement. Rights may be exercised at
any time up to the close of business on the expiration date for the
rights provided in the applicable prospectus supplement. After the
close of business on the expiration date, all unexercised rights
will become void.
Holders may exercise rights as described in the applicable
prospectus supplement. Upon receipt of payment and the rights
certificate properly completed and duly executed at the corporate
trust office of the rights agent, if any, or any other office
indicated in the prospectus supplement, we will, as soon as
practicable, forward the securities purchasable upon exercise of
the rights. If less than all of the rights issued in any rights
offering are exercised, we may offer any unsubscribed securities
directly to persons other than stockholders, to or through agents,
underwriters or dealers or through a combination of such methods,
including pursuant to standby underwriting arrangements, as
described in the applicable prospectus supplement.
Depositary
Shares
General. We may offer fractional shares of preferred stock,
rather than full shares of preferred stock. If we decide to offer
fractional shares of our preferred stock, we will issue receipts
for depositary shares. Each depositary share will represent a
fraction of a share of a particular series of our preferred stock,
and the applicable prospectus supplement will indicate that
fraction. The shares of preferred stock represented by depositary
shares will be deposited under a deposit agreement between us and a
depositary that is a bank or trust company that meets certain
requirements and is selected by us. The depositary will be
specified in the applicable prospectus supplement. Each owner of a
depositary share will be entitled to all of the rights and
preferences of the preferred stock represented by the depositary
share. The depositary shares will be evidenced by depositary
receipts issued pursuant to the deposit agreement. Depositary
receipts will be distributed to those persons purchasing the
fractional shares of our preferred stock in accordance with the
terms of the offering. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate
by reference from a current report on Form 8-K that we file with
the Commission, forms of the deposit agreement, form of certificate
of designation of underlying preferred stock, form of depositary
receipts and any other related agreements.
Dividends and Other Distributions. The depositary
will distribute all cash dividends or other cash distributions
received by it in respect of the preferred stock to the record
holders of depositary shares relating to such preferred shares in
proportion to the numbers of depositary shares held on the relevant
record date.
In the event of a distribution other than in cash, the depositary
will distribute securities or property received by it to the record
holders of depositary shares in proportion to the numbers of
depositary shares held on the relevant record date, unless the
depositary determines that it is not feasible to make such
distribution. In that case, the depositary may make the
distribution by such method as it deems equitable and practicable.
One such possible method is for the depositary to sell the
securities or property and then distribute the net proceeds from
the sale as provided in the case of a cash distribution.
Redemption of Depositary Shares. Whenever we redeem
the preferred stock, the depositary will redeem a number of
depositary shares representing the same number of shares of
preferred stock so redeemed. If fewer than all of the depositary
shares are to be redeemed, the depositary shares to be redeemed
will be selected by lot, pro rata or by any other equitable method
as the depositary may determine.
Voting of Underlying Shares. Upon receipt of notice of any
meeting at which the holders of our preferred stock of any series
are entitled to vote, the depositary will mail the information
contained in the notice of the meeting to the record holders of the
depositary shares relating to that series of preferred stock. Each
record holder of the depositary shares on the record date will be
entitled to instruct the depositary as to the exercise of the
voting rights represented by the number of shares of preferred
stock underlying the holder’s depositary shares. The depositary
will endeavor, to the extent it is practical to do so, to vote the
number of whole shares of preferred stock underlying such
depositary shares in accordance with such instructions. We will
agree to take all action that the depositary may deem reasonably
necessary in order to enable the depositary to do so. To the extent
the depositary does not receive specific instructions from the
holders of depositary shares relating to such preferred shares, it
will abstain from voting such shares of preferred stock.
Withdrawal of Shares. Upon surrender of depositary receipts
representing any number of whole shares at the depositary’s office,
unless the related depositary shares previously have been called
for redemption, the holder of the depositary shares evidenced by
the depositary receipts will be entitled to delivery of the number
of whole shares of the related series of preferred stock and all
money and other property, if any, underlying such depositary
shares. However, once such an exchange is made, the preferred stock
cannot thereafter be re-deposited in exchange for depositary
shares. Holders of depositary shares will be entitled to receive
whole shares of the related series of preferred stock on the basis
set forth in the applicable prospectus supplement. If the
depositary receipts delivered by the holder evidence a number of
depositary shares representing more than the number of whole shares
of preferred stock of the related series to be withdrawn, the
depositary will deliver to the holder at the same time a new
depositary receipt evidencing the excess number of depositary
shares.
Amendment and Termination of Depositary Agreement.
The form of depositary receipt evidencing the depositary shares and
any provision of the applicable depositary agreement may at any
time be amended by agreement between us and the depositary. We may,
with the consent of the depositary, amend the depositary agreement
from time to time in any manner that we desire. However, if the
amendment would materially and adversely alter the rights of the
existing holders of depositary shares, the amendment would need to
be approved by the holders of at least a majority of the depositary
shares then outstanding.
The depositary agreement may be terminated by us or the depositary
if:
|
● |
all outstanding depositary shares
have been redeemed; or |
|
|
|
|
● |
there has been a final
distribution in respect of the shares of preferred stock of the
applicable series in connection with our liquidation, dissolution
or winding up and such distribution has been made to the holders of
depositary receipts. |
Resignation and Removal of Depositary. The depositary may
resign at any time by delivering to us notice of its election to do
so. We may remove a depositary at any time. Any resignation or
removal will take effect upon the appointment of a successor
depositary and its acceptance of appointment.
Charges of Depositary. We will pay all transfer and other
taxes and governmental charges arising solely from the existence of
any depositary arrangements. We will pay all charges of each
depositary in connection with the initial deposit of the preferred
shares of any series, the initial issuance of the depositary
shares, any redemption of such preferred shares and any withdrawals
of such preferred shares by holders of depositary shares. Holders
of depositary shares will be required to pay any other transfer
taxes.
Notices. Each depositary will forward to the holders of the
applicable depositary shares all notices, reports and
communications from us which are delivered to such depositary and
which we are required to furnish the holders of the preferred stock
represented by such depositary shares.
Miscellaneous. The depositary agreement may contain
provisions that limit our liability and the liability of the
depositary to the holders of depositary shares. Both the depositary
and we are also entitled to an indemnity from the holders of the
depositary shares prior to bringing, or defending against, any
legal proceeding. We or any depositary may rely upon written advice
of counsel or accountants, or information provided by persons
presenting preferred shares for deposit, holders of depositary
shares or other persons believed by us to be competent and on
documents believed by us or them to be genuine.
Purchase
Contracts
We may issue purchase contracts, representing contracts obligating
holders to purchase from us, and us to sell to the holders, a
specific or varying number of common stock, preferred stock,
warrants, depositary shares or any combination of the above, at a
future date or dates. Alternatively, the purchase contracts may
obligate us to purchase from holders, and obligate holders to sell
to us, a specific or varying number of common stock, preferred
stock, warrants, depositary shares, or any combination of the
above. The price of the securities and other property subject to
the purchase contracts may be fixed at the time the purchase
contracts are issued or may be determined by reference to a
specific formula set forth in the purchase contracts. The purchase
contracts may be issued separately or as a part of a unit that
consists of (a) a purchase contract and (b) one or more of the
other securities that may be sold by us pursuant to this prospectus
or any combination of the foregoing, which may secure the holders’
obligations to purchase the securities under the purchase contract.
The purchase contracts may require us to make periodic payments to
the holders or require the holders to make periodic payments to us.
These payments may be unsecured or prefunded and may be paid on a
current or on a deferred basis. The purchase contracts may require
holders to secure their obligations under the contracts in a manner
specified in the applicable prospectus supplement.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from a
current report on Form 8-K that we file with the Commission, forms
of the purchase contracts and purchase contract agreement, if any.
The applicable prospectus supplement will describe the terms of any
purchase contracts in respect of which this prospectus is being
delivered, including, to the extent applicable, the following:
|
● |
whether the purchase contracts
obligate the holder or us to purchase or sell, or both purchase and
sell, the securities subject to purchase under the purchase
contract, and the nature and amount of each of those securities, or
the method of determining those amounts; |
|
|
|
|
● |
whether the purchase contracts
are to be prepaid or not; |
|
|
|
|
● |
whether
the purchase contracts are to be settled by delivery, or by
reference or linkage to the value, performance or level of the
securities subject to purchase under the purchase
contract; |
|
|
|
|
● |
any acceleration, cancellation,
termination or other provisions relating to the settlement of the
purchase contracts; |
|
|
|
|
● |
whether the purchase contracts
will be issued in fully registered or global form; and |
|
|
|
|
● |
any applicable federal income tax
considerations; and |
Units
We may issue units consisting of any combination of the other types
of securities offered under this prospectus in one or more series.
We may evidence each series of units by unit certificates that we
may issue under a separate agreement. We may enter into unit
agreements with a unit agent. Each unit agent, if any, may be a
bank or trust company that we select. We will indicate the name and
address of the unit agent, if any, in the applicable prospectus
supplement relating to a particular series of units. Specific unit
agreements, if any, will contain additional important terms and
provisions. We will file as an exhibit to the registration
statement of which this prospectus is a part, or will incorporate
by reference from a current report that we file with the
Commission, the form of unit and the form of each unit agreement,
if any, relating to units offered under this prospectus.
If we offer any units, certain terms of that series of units will
be described in the applicable prospectus supplement, including,
without limitation, the following, as applicable
|
● |
the title of the series of
units; |
|
|
|
|
● |
identification and description of
the separate constituent securities comprising the
units; |
|
|
|
|
● |
the price or prices at which the
units will be issued; |
|
|
|
|
● |
the date, if any, on and after
which the constituent securities comprising the units will be
separately transferable; |
|
|
|
|
● |
a discussion of certain United
States federal income tax considerations applicable to the units;
and |
|
|
|
|
● |
any other material terms of the
units and their constituent securities. |
Anti-takeover Effects of Our Articles of Incorporation and
By-laws
Our Articles of Incorporation and Bylaws contain certain provisions
that may have anti-takeover effects, making it more difficult for
or preventing a third party from acquiring control of our Company
or changing our Board of Directors and management. According to our
Bylaws and Articles of Incorporation, neither the holders of our
common stock nor the holders of our preferred stock have cumulative
voting rights in the election of our directors. The combination of
the present ownership by a few stockholders of a significant
portion of our issued and outstanding common stock and lack of
cumulative voting makes it more difficult for other stockholders to
replace our Board of Directors or for a third party to obtain
control of our Company by replacing our Board of Directors.
Anti-takeover Effects of Nevada Law
Business Combinations
The “business combination” provisions of Sections 78.411 to 78.444,
inclusive, of the Nevada Revised Statutes, or NRS, generally
prohibit a Nevada corporation with at least 200 stockholders of
record, a “resident domestic corporation,” from engaging in various
“combination” transactions with any “interested stockholder” unless
certain conditions are met or the corporation has elected in its
articles of incorporation to not be subject to these
provisions.
A “combination” is generally defined to include (a) a merger or
consolidation of the resident domestic corporation or any
subsidiary of the resident domestic corporation with the interested
stockholder or affiliate or associate of the interested
stockholder; (b) any sale, lease, exchange, mortgage, pledge,
transfer, or other disposition, in one transaction or a series of
transactions, by the resident domestic corporation or any
subsidiary of the resident domestic corporation to or with the
interested stockholder or affiliate or associate of the interested
stockholder having: (i) an aggregate market value equal to 5% or
more of the aggregate market value of the assets of the resident
domestic corporation, (ii) an aggregate market value equal to 5% or
more of the aggregate market value of all outstanding shares of the
resident domestic corporation, or (iii) 10% or more of the earning
power or net income of the resident domestic corporation; (c) the
issuance or transfer in one transaction or series of transactions
of shares of the resident domestic corporation or any subsidiary of
the resident domestic corporation having an aggregate market value
equal to 5% or more of the resident domestic corporation to the
interested stockholder or affiliate or associate of the interested
stockholder; and (d) certain other transactions with an interested
stockholder or affiliate or associate of the interested
stockholder.
An “interested stockholder” is generally defined as a person who,
together with affiliates and associates, owns (or within three
years, did own) 10% or more of a corporation’s voting stock. An
“affiliate” of the interested stockholder is any person that
directly or indirectly through one or more intermediaries is
controlled by or is under common control with the interested
stockholder. An “associate” of an interested stockholder is any (a)
corporation or organization of which the interested stockholder is
an officer or partner or is directly or indirectly the beneficial
owner of 10% or more of any class of voting shares of such
corporation or organization; (b) trust or other estate in which the
interested stockholder has a substantial beneficial interest or as
to which the interested stockholder serves as trustee or in a
similar fiduciary capacity; or (c) relative or spouse of the
interested stockholder, or any relative of the spouse of the
interested stockholder, who has the same home as the interested
stockholder.
If applicable, the prohibition is for a period of two years after
the date of the transaction in which the person became an
interested stockholder, unless such transaction is approved by the
board of directors prior to the date the interested stockholder
obtained such status; or the combination is approved by the board
of directors and thereafter is approved at a meeting of the
stockholders by the affirmative vote of stockholders representing
at least 60% of the outstanding voting power held by disinterested
stockholders; and extends beyond the expiration of the two-year
period, unless (a) the combination was approved by the board of
directors prior to the person becoming an interested stockholder;
(b) the transaction by which the person first became an interested
stockholder was approved by the board of directors before the
person became an interested stockholder; (c) the transaction is
approved by the affirmative vote of a majority of the voting power
held by disinterested stockholders at a meeting called for that
purpose no earlier than two years after the date the person first
became an interested stockholder; or (d) if the consideration to be
paid to all stockholders other than the interested stockholder is,
generally, at least equal to the highest of: (i) the highest price
per share paid by the interested stockholder within the three years
immediately preceding the date of the announcement of the
combination or in the transaction in which it became an interested
stockholder, whichever is higher, plus compounded interest and less
dividends paid, (ii) the market value per share of common shares on
the date of announcement of the combination and the date the
interested stockholder acquired the shares, whichever is higher,
plus compounded interest and less dividends paid, or (iii) for
holders of preferred stock, the highest liquidation value of the
preferred stock, plus accrued dividends, if not included in the
liquidation value. With respect to (i) and (ii) above, the interest
is compounded at the rate for one-year United States Treasury
obligations from time to time in effect.
Applicability of the Nevada business combination law would
discourage parties interested in taking control of our company if
they cannot obtain the approval of our board of directors. These
provisions could prohibit or delay a merger or other takeover or
change in control attempt and, accordingly, may discourage attempts
to acquire our company even though such a transaction may offer our
stockholders the opportunity to sell their stock at a price above
the prevailing market price.
Control Share Acquisitions
The “control share” provisions of Sections 78.378 to 78.3793,
inclusive, of the NRS, apply to “issuing corporations,” which are
Nevada corporations with at least 200 stockholders of record,
including at least 100 stockholders of record who are Nevada
residents, and which conduct business directly or indirectly in
Nevada, unless the corporation has elected to not be subject to
these provisions.
The control share statute prohibits an acquirer of shares of an
issuing corporation, under certain circumstances, from voting its
shares of a corporation’s stock after crossing certain ownership
threshold percentages, unless the acquirer obtains approval of the
target corporation’s disinterested stockholders. The statute
specifies three thresholds: (a) one-fifth or more but less than
one-third, (b) one-third but less than a majority, and (c) a
majority or more, of the outstanding voting power. Generally, once
a person acquires shares in excess of any of the thresholds, those
shares and any additional shares acquired within 90 days thereof
become “control shares” and such control shares are deprived of the
right to vote until disinterested stockholders restore the right.
These provisions also provide that if control shares are accorded
full voting rights and the acquiring person has acquired a majority
or more of all voting power, all other stockholders who do not vote
in favor of authorizing voting rights to the control shares are
entitled to demand payment for the fair value of their shares in
accordance with statutory procedures established for dissenters’
rights.
A corporation may elect to not be governed by, or “opt out” of, the
control share provisions by making an election in its articles of
incorporation or bylaws, provided that the opt-out election must be
in place on the 10th day following the date an acquiring person has
acquired a controlling interest, that is, crossing any of the three
thresholds described above. We have not opted out of the control
share statutes.
The effect of the Nevada control share statute is that the
acquiring person, and those acting in association with the
acquiring person, will obtain only such voting rights in the
control shares as are conferred by a resolution of the stockholders
at an annual or special meeting. The Nevada control share law, if
applicable, could have the effect of discouraging takeovers of our
company.
Listing
Our common stock is traded on OTC Pink market under the symbol
“CLWD.”
Transfer Agent
The transfer agent and registrar for our common stock is Worldwide
Stock Transfer, LLC. The transfer agent’s address 1 University
Plaza Suite 505, Hackensack, NJ 07601 and its telephone number is
+1-201-820-2008.
FORMS OF
SECURITIES
Each security may be represented either by a certificate issued in
definitive form to a particular investor or by one or more global
securities representing the entire issuance of securities.
Certificated securities in definitive form and global securities
will be issued in registered form. Definitive securities name you
or your nominee as the owner of the security, and in order to
transfer or exchange these securities or to receive payments other
than interest or other interim payments, you or your nominee must
physically deliver the securities to the trustee, registrar, paying
agent or other agent, as applicable. Global securities name a
depositary or its nominee as the owner of the warrants or units
represented by these global securities. The depositary maintains a
computerized system that will reflect each investor’s beneficial
ownership of the securities through an account maintained by the
investor with its broker/dealer, bank, trust company or other
representative, as we explain more fully below.
Registered Global Securities
We may issue the securities in the form of one or more fully
registered global securities that will be deposited with a
depositary or its nominee identified in the applicable prospectus
supplement and registered in the name of that depositary or
nominee. In those cases, one or more registered global securities
will be issued in a denomination or aggregate denominations equal
to the portion of the aggregate principal or face amount of the
securities to be represented by registered global securities.
Unless and until it is exchanged in whole for securities in
definitive registered form, a registered global security may not be
transferred except as a whole by and among the depositary for the
registered global security, the nominees of the depositary or any
successors of the depositary or those nominees.
The specific terms of the depositary arrangement with respect to
any securities to be represented by a registered global security
will be described in the prospectus supplement relating to those
securities. We anticipate that the following provisions will apply
to all depositary arrangements.
Ownership of beneficial interests in a registered global security
will be limited to persons, called participants, that have accounts
with the depositary or persons that may hold interests through
participants. Upon the issuance of a registered global security,
the depositary will credit, on its book-entry registration and
transfer system, the participants’ accounts with the respective
principal or face amounts of the securities beneficially owned by
the participants. Any dealers, underwriters or agents participating
in the distribution of the securities will designate the accounts
to be credited. Ownership of beneficial interests in a registered
global security will be shown on, and the transfer of ownership
interests will be effected only through, records maintained by the
depositary, with respect to interests of participants, and on the
records of participants, with respect to interests of persons
holding through participants. The laws of some states may require
that some purchasers of securities take physical delivery of these
securities in definitive form. These laws may impair your ability
to own, transfer or pledge beneficial interests in registered
global securities.
So long as the depositary, or its nominee, is the registered owner
of a registered global security, that depositary or its nominee, as
the case may be, will be considered the sole owner or holder of the
securities represented by the registered global security for all
purposes under the applicable indenture, warrant agreement or unit
agreement.
Except as described below, owners of beneficial interests in a
registered global security will not be entitled to have the
securities represented by the registered global security registered
in their names, will not receive or be entitled to receive physical
delivery of the securities in definitive form and will not be
considered the owners or holders of the securities under the
applicable indenture, warrant agreement or unit agreement.
Accordingly, each person owning a beneficial interest in a
registered global security must rely on the procedures of the
depositary for that registered global security and, if that person
is not a participant, on the procedures of the participant through
which the person owns its interest, to exercise any rights of a
holder under the applicable indenture, warrant agreement or unit
agreement. We understand that under existing industry practices, if
we request any action of holders or if an owner of a beneficial
interest in a registered global security desires to give or take
any action that a holder is entitled to give or take under the
applicable indenture, warrant agreement or unit agreement, the
depositary for the registered global security would authorize the
participants holding the relevant beneficial interests to give or
take that action, and the participants would authorize beneficial
owners owning through them to give or take that action or would
otherwise act upon the instructions of beneficial owners holding
through them.
Payments to holders with respect to securities represented by a
registered global security registered in the name of a depositary
or its nominee will be made to the depositary or its nominee, as
the case may be, as the registered owner of the registered global
security. None of the Company, the trustees, the warrant agents,
the unit agents or any other agent of the Company, agent of the
trustees, the warrant agents or unit agents will have any
responsibility or liability for any aspect of the records relating
to payments made on account of beneficial ownership interests in
the registered global security or for maintaining, supervising or
reviewing any records relating to those beneficial ownership
interests.
We expect that the depositary for any of the securities represented
by a registered global security, upon receipt of any payment of
principal, premium, interest or other payment or distribution to
holders of that registered global security, will immediately credit
participants’ accounts in amounts proportionate to their respective
beneficial interests in that registered global security as shown on
the records of the depositary. We also expect that payments by
participants to owners of beneficial interests in a registered
global security held through participants will be governed by
standing customer instructions and customary practices, as is now
the case with the securities held for the accounts of customers or
registered in “street name,” and will be the responsibility of
those participants.
If the depositary for any of these securities represented by a
registered global security is at any time unwilling or unable to
continue as depositary or ceases to be a clearing agency registered
under the Exchange Act and a successor depositary registered as a
clearing agency under the Exchange Act is not appointed by us
within 90 days, we will issue securities in definitive form in
exchange for the registered global security that had been held by
the depositary. Any securities issued in definitive form in
exchange for a registered global security will be registered in the
name or names that the depositary gives to the relevant trustee,
warrant agent, unit agent or other relevant agent of ours or
theirs. It is expected that the depositary’s instructions will be
based upon directions received by the depositary from participants
with respect to ownership of beneficial interests in the registered
global security that had been held by the depositary.
LEGAL
MATTERS
Unless otherwise indicated in the applicable prospectus supplement,
the validity of the securities offered by this prospectus and
certain other legal matters as to Nevada law will be passed upon
for us by Sichenzia Ross Ference LLP, New York, New York. If legal
matters in connection with offerings made by this prospectus are
passed on by counsel for the underwriters, dealers or agents, if
any, that counsel will be named in the applicable prospectus
supplement.
EXPERTS
The financial statements incorporated by reference into this
prospectus have been so included in reliance on the reports of
M&K CPAs, PLLC, an independent registered public accounting
firm, related to the consolidated financial statements as of
December 31, 2019 and 2018 and for the years then ended, given
on the authority of said firm as experts in auditing and
accounting.
WHERE YOU CAN FIND
MORE INFORMATION
We file annual, quarterly and special reports, along with other
information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC’s website at
http://www.sec.gov.
This prospectus is part of a registration statement on Form S-3
that we filed with the SEC to register the securities offered
hereby under the Securities Act of 1933, as amended. This
prospectus does not contain all of the information included in the
registration statement, including certain exhibits and schedules.
You may obtain the registration statement and exhibits to the
registration statement from the SEC from the SEC’s internet
site.
INCORPORATION OF
DOCUMENTS BY REFERENCE
We are “incorporating by reference” in this prospectus certain
documents we file with the Commission, which means that we can
disclose important information to you by referring you to those
documents. The information in the documents incorporated by
reference is considered to be part of this prospectus. Statements
contained in documents that we file with the Commission and that
are incorporated by reference in this prospectus will automatically
update and supersede information contained in this prospectus,
including information in previously filed documents or reports that
have been incorporated by reference in this prospectus, to the
extent the new information differs from or is inconsistent with the
old information. We have filed or may file the following documents
with the Commission and they are incorporated herein by reference
as of their respective dates of filing.
|
● |
Our
Annual Report on
Form 10-K for the fiscal year ended December 31, 2019, filed
with the Commission on April 16, 2020, as amended by
Form 10K/A filed with the Commission on May 22,
2020; |
|
● |
Our
Quarterly Reports on Form 10-Q for the quarterly period ended March
31, 2020, filed with the Commission on
May 15, 2020, for the quarterly period ended June 30, 2020,
filed with the Commission on
August 14, 2020, and for the quarterly period ended September
30, 2020, filed with the Commission on
November 13, 2020; and |
|
● |
Our
Current Reports on Form 8-K and 8-K/A filed with the Commission
April 29, 2020,
May 12, 2020,
May 20, 2020,
June 16, 2020,
June 18, 2020,
June 24, 2020,
June 26, 2020,
July 15, 2020,
July 20, 2020,
July 28, 2020,
October 28, 2020,
January 11, 2021, and
January 15, 2021.,
February 2, 2021, and
February 9, 2021. |
All documents that we filed with the Commission pursuant to
Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act subsequent
to the date of this registration statement and prior to the filing
of a post-effective amendment to this registration statement that
indicates that all securities offered under this prospectus have
been sold, or that deregisters all securities then remaining
unsold, will be deemed to be incorporated in this registration
statement by reference and to be a part hereof from the date of
filing of such documents.
Any statement contained in a document incorporated or deemed to be
incorporated by reference in this prospectus shall be deemed
modified, superseded or replaced for purposes of this prospectus to
the extent that a statement contained in this prospectus, or in any
subsequently filed document that also is deemed to be incorporated
by reference in this prospectus, modifies, supersedes or replaces
such statement. Any statement so modified, superseded or replaced
shall not be deemed, except as so modified, superseded or replaced,
to constitute a part of this prospectus. None of the information
that we disclose under Items 2.02 or 7.01 of any Current Report on
Form 8-K or any corresponding information, either furnished under
Item 9.01 or included as an exhibit therein, that we may from time
to time furnish to the Commission will be incorporated by reference
into, or otherwise included in, this prospectus, except as
otherwise expressly set forth in the relevant document. Subject to
the foregoing, all information appearing in this prospectus is
qualified in its entirety by the information appearing in the
documents incorporated by reference.
You may request, orally or in writing, a copy of these documents,
which will be provided to you at no cost (other than exhibits,
unless such exhibits are specifically incorporate by reference), by
contacting our chief financial officer, c/o CloudCommerce, Inc., at
321 Sixth Street, San Antonio, TX 78215. Our telephone
number is +1-805-964-3313. Information about us is also available
at our website at www.cloudcommerce.com. However, the
information in our website is not a part of this prospectus and is
not incorporated by reference.

Up to $10,000,000 of Shares of Common Stock
PROSPECTUS SUPPLEMENT
March 28, 2022
Aiadvertising (PK) (USOTC:AIAD)
Historical Stock Chart
From May 2022 to Jun 2022
Aiadvertising (PK) (USOTC:AIAD)
Historical Stock Chart
From Jun 2021 to Jun 2022